Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-Q


ý

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 29, 2008

OR

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                             to                            

Commission File Number: 1-5742

RITE AID CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
  23-1614034
(I.R.S. Employer
Identification No.)

30 Hunter Lane,
Camp Hill, Pennsylvania

(Address of principal executive offices)

 


17011

(Zip Code)

Registrant's telephone number, including area code: (717) 761-2633.

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):
Not Applicable

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes  ý     No  o

        Indicate by check whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See the definition of "Accelerated Filer" and "Large Accelerated Filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ý   Accelerated filer  o   Non-accelerated filer  o
(Do not check if a smaller reporting company)
  Smaller reporting company  o

        Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act). Yes  o     No  ý

        Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

        The registrant had 859,127,715 shares of its $1.00 par value common stock outstanding as of January 5, 2009.


Table of Contents

RITE AID CORPORATION

TABLE OF CONTENTS

 

Cautionary Statement Regarding Forward-Looking Statements

  3

PART I
FINANCIAL INFORMATION

ITEM 1.

 

Financial Statements (unaudited):

   

 

Condensed Consolidated Balance Sheets as of November 29, 2008 and March 1, 2008

 
5

 

Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended November 29, 2008 and December 1, 2007

 
6

 

Condensed Consolidated Statements of Operations for the Thirty-nine Week Periods Ended November 29, 2008 and December 1, 2007

 
7

 

Condensed Consolidated Statements of Cash Flows for the Thirty-nine Week Periods Ended November 29, 2008 and December 1, 2007

 
8

 

Notes to Condensed Consolidated Financial Statements

 
9

ITEM 2.

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

 
28

ITEM 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 
40

ITEM 4.

 

Controls and Procedures

 
41

PART II
OTHER INFORMATION

ITEM 1.

 

Legal Proceedings

 
42

ITEM 1A.

 

Risk Factors

 
42

ITEM 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 
42

ITEM 3.

 

Defaults Upon Senior Securities

 
43

ITEM 4.

 

Submission of Matters to a Vote of Security Holders

 
43

ITEM 5.

 

Other Information

 
43

ITEM 6.

 

Exhibits

 
43

2


Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

        This report, as well as our other public filings or public statements, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by terms and phrases such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "should," "could," "may," "plan," "project," "predict," "will" and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

        Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

3


Table of Contents

        We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included herein and included in our Annual Report on Form 10-K for the fiscal year ended March 1, 2008 ("the Fiscal 2008 10-K"), which we filed with the SEC on April 29, 2008 and in the section entitled "Risk Factors" included in our Quarterly Report for the thirteen and twenty-six weeks ended August 30, 2008, which we filed with the SEC on October 8, 2008. These documents are available on the SEC's website at www.sec.gov.

4


Table of Contents


PART I. FINANCIAL INFORMATION

ITEM 1.    Financial Statements

RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
(unaudited)

 
  November 29,
2008
  March 1,
2008
 

ASSETS

             

Current assets:

             
 

Cash and cash equivalents

  $ 148,860   $ 155,762  
 

Accounts receivable, net

    592,323     665,971  
 

Inventories, net of LIFO reserve of $652,729 and $562,729

    3,982,628     3,936,827  
 

Prepaid expenses and other current assets

    96,543     163,334  
           
   

Total current assets

    4,820,354     4,921,894  

Property, plant and equipment, net

    2,725,778     2,873,009  

Goodwill

    1,810,223     1,783,372  

Other intangibles, net

    1,087,723     1,187,327  

Deferred tax assets

    328,478     384,163  

Other assets

    353,480     338,258  
           
   

Total assets

  $ 11,126,036   $ 11,488,023  
           

LIABILITIES AND STOCKHOLDERS' EQUITY

             

Current liabilities:

             
 

Current maturities of long-term debt and lease financing obligations

  $ 42,065   $ 185,609  
 

Accounts payable

    1,311,263     1,425,768  
 

Accrued salaries, wages and other current liabilities

    1,075,115     1,110,288  
 

Defered tax liabilities

    47,744     76,374  
           
   

Total current liabilities

    2,476,187     2,798,039  

Long-term debt, less current maturities

    6,109,553     5,610,489  

Lease financing obligations, less current maturities

    196,035     189,426  

Other noncurrent liabilities

    1,233,082     1,178,884  
           
   

Total liabilities

    10,014,857     9,776,838  

Commitments and contingencies

         

Stockholders' equity:

             
 

Preferred stock—series G, par value $1 per share, liquidation value $100 per share; 2,000 shares authorized; shares issued 1,467 and 1,393

    146,692     139,253  
 

Preferred stock—series H, par value $1 per share, liquidation value $100 per share; 2,000 shares authorized; shares issued 1,414 and 1,352

    141,378     135,202  
 

Preferred stock—series I, par value $1 per share, liquidation value $25 per share; 5,200 shares authorized; shares issued 0 and 4,820

        116,415  
 

Common stock, par value $1 per share; 1,500,000 authorized; shares issued and outstanding 859,212 and 830,209

    859,212     830,209  

Additional paid-in capital

    4,142,056     4,047,499  

Accumulated deficit

    (4,159,051 )   (3,537,276 )

Accumulated other comprehensive loss

    (19,108 )   (20,117 )
           
 

Total stockholders' equity

    1,111,179     1,711,185  
           
 

Total liabilities and stockholders' equity

  $ 11,126,036   $ 11,488,023  
           

See accompanying notes to condensed consolidated financial statements.

5


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

 
  Thirteen Week Period Ended  
 
  November 29,
2008
  December 1,
2007
 

Revenues

  $ 6,468,601   $ 6,497,912  

Costs and expenses:

             
 

Cost of goods sold

    4,743,089     4,754,057  
 

Selling, general and administrative expenses

    1,711,873     1,730,053  
 

Lease termination and impairment charges

    101,635     21,836  
 

Interest expense

    126,615     130,306  
 

Gain on sale of assets, net

    (1,008 )   (2,105 )
           

    6,682,204     6,634,147  
           

Loss from continuing operations before income taxes

    (213,603 )   (136,235 )

Income tax expense (benefit)

    29,522     (52,740 )
           
 

Net loss from continuing operations

  $ (243,125 ) $ (83,495 )

Loss from discontinued operations, net of tax

        (1,351 )
           

Net loss

  $ (243,125 ) $ (84,846 )
           

Computation of loss attributable to common stockholders:

             
 

Net loss

  $ (243,125 ) $ (84,846 )
 

Accretion of redeemable preferred stock

    (26 )   (26 )
 

Cumulative preferred stock dividends

    (5,591 )   (8,168 )
           
 

Loss attributable to common stockholders—basic and diluted

  $ (248,742 ) $ (93,040 )
           
 

Basic and diluted loss per share

  $ (0.30 ) $ (0.12 )
           

See accompanying notes to condensed consolidated financial statements.

6


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(In thousands, except per share amounts)

(unaudited)

 
  Thirty-Nine Week Period Ended  
 
  November 29,
2008
  December 1,
2007
 

Revenues

  $ 19,581,701   $ 17,502,024  

Costs and expenses:

             
 

Cost of goods sold

    14,269,769     12,752,779  
 

Selling, general and administrative expenses

    5,285,478     4,591,843  
 

Lease termination and impairment charges

    189,722     42,453  
 

Interest expense

    363,420     322,281  
 

Loss on debt modifications and retirements, net

    39,905     12,900  
 

Loss (gain) on sale of assets, net

    11,939     (4,684 )
           

    20,160,233     17,717,572  
           

Loss from continuing operations before income taxes

    (578,532 )   (215,548 )

Income tax expense (benefit)

    39,861     (92,210 )
           
 

Net loss from continuing operations

  $ (618,393 ) $ (123,338 )

Loss from discontinued operations, net of tax

    (3,369 )   (3,472 )
           

Net loss

  $ (621,762 ) $ (126,810 )
           

Computation of loss attributable to common stockholders:

             
 

Net loss

  $ (621,762 ) $ (126,810 )
 

Accretion of redeemable preferred stock

    (77 )   (77 )
 

Cumulative preferred stock dividends

    (17,081 )   (24,295 )
 

Preferred stock beneficial conversion

        (556 )
           
 

Loss attributable to common stockholders—basic and diluted

  $ (638,920 ) $ (151,738 )
           
 

Basic and diluted loss per share

  $ (0.77 ) $ (0.22 )
           

See accompanying notes to condensed consolidated financial statements.

7


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

 
  Thirty-Nine Week Period Ended  
 
  November 29,
2008
  December 1,
2007
 

Operating activities:

             
 

Net loss

  $ (621,762 ) $ (126,810 )
 

Adjustments to reconcile to net cash provided by (used in) operating activities:

             
   

Depreciation and amortization

    441,349     337,941  
   

Lease termination and impairment charges

    189,722     42,453  
   

LIFO charges

    90,000     41,373  
   

Loss (gain) on sale of assets and investments, net

    11,987     (4,684 )
   

Stock-based compensation expense

    25,921     27,618  
   

Loss on debt modifications and retirements, net

    39,905     12,900  
   

Changes in deferred taxes

    27,055     (89,872 )
   

Proceeds from insured loss

        8,550  
   

Changes in operating assets and liabilities:

             
     

Net proceeds from accounts receivable securitization

    110,000     50,000  
     

Proceeds from the sale of inventory

        8,156  
     

Accounts receivable

    (36,916 )   8,044  
     

Inventories

    (182,038 )   (561,144 )
     

Accounts payable

    (52,264 )   (39,837 )
     

Other assets and liabilities, net

    (7,827 )   55,237  
           
       

Net cash provided by (used in) operating activities

    35,132     (230,075 )
           

Investing activities:

             
 

Payments for property, plant and equipment

    (401,460 )   (478,431 )
 

Intangible assets acquired

    (75,454 )   (40,737 )
 

Acquisition of Jean Coutu USA, net of cash acquired

    (112 )   (2,306,554 )
 

Proceeds from sale-leaseback transactions

    161,553     20,757  
 

Proceeds from dispositions of assets and investments

    22,904     23,566  
 

Proceeds from insured loss

        5,950  
           
       

Net cash used in investing activities

    (292,569 )   (2,775,449 )
           

Financing activities:

             
 

Proceeds from issuance of long-term debt

    900,629     2,306,005  
 

Net proceeds from revolver

    297,000     708,000  
 

Proceeds from financing secured by owned property

    31,266      
 

Principal payments on long-term debt

    (862,162 )   (10,919 )
 

Change in zero balance cash accounts

    (64,376 )   121,058  
 

Excess tax deduction on stock options

        5,882  
 

Net proceeds from issuance of common stock

    1,117     12,722  
 

Payments for preferred stock dividends

    (3,466 )   (11,535 )
 

Financing costs paid

    (49,473 )   (58,195 )
           
       

Net cash provided by financing activities

    250,535     3,073,018  
           

(Decrease) increase in cash and cash equivalents

    (6,902 )   67,494  

Cash and cash equivalents, beginning of period

    155,762     106,148  
           

Cash and cash equivalents, end of period

  $ 148,860   $ 173,642  
           

Supplementary cash flow data:

             
 

Cash paid for interest (net of capitalized amounts of $1,248 and $1,515, respectively)

  $ 303,334   $ 206,974  
           
 

Cash payments of income taxes, net of refunds

  $ 2,776   $ 2,762  
           
 

Equipment financed under capital leases

  $ 6,014   $ 6,357  
           
 

Equipment received for noncash consideration

  $ 23,081   $ 290  
           
 

Reduction in lease financing obligation

  $ 17,021   $ 30,520  
           
 

Preferred stock dividends paid in additional shares

  $ 13,615   $ 12,760  
           

See accompanying notes to condensed consolidated financial statements.

8


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

1.    Basis of Presentation

        The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen and thirty-nine week periods ended November 29, 2008 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Fiscal 2008 10-K.

2.    Recent Accounting Pronouncements

        In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". This standard establishes a standard definition for fair value, establishes a framework under generally accepted accounting principles for measuring fair value and expands disclosure requirements for fair value measurements. This standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. In December 2007, a FASB Staff Position (FSP) was proposed, and subsequently approved, to delay the effective dates of SFAS No. 157 as it relates to all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, or at least annually. The Company has adopted SFAS No. 157 as of March 2, 2008 as it relates to financial assets and liabilities and there was no impact on the financial statements. The Company is currently evaluating the impact of SFAS No.157 on nonfinancial assets and liabilities and expects the adoption to have an impact on fair value calculations used in its testing of goodwill, intangibles and fixed assets for impairment.

        In December 2007, the FASB issued SFAS No. 141 (Revised) "Business Combinations". SFAS 141 (Revised) establishes principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the assets acquired and liabilities assumed in a business combination and makes several changes to the method of accounting for business combinations previously set forth in SFAS No. 141. SFAS No. 141 (Revised) will become effective for acquisitions consummated in fiscal years beginning after December 15, 2008.

3.    Acquisition

        On June 4, 2007, the Company acquired of all of the membership interests of JCG (PJC) USA, LLC ("Jean Coutu USA") the holding company for the Brooks Eckerd drugstore chain ("Brooks Eckerd"), from Jean Coutu Group (PJC) Inc. ("Jean Coutu Group"), pursuant to the terms of the Stock Purchase Agreement (the "Agreement") dated August 23, 2006. As consideration for the acquisition of Jean Coutu USA (the "Acquisition"), the Company paid $2,307,747 and issued 250,000 shares of Rite Aid common stock. The Company financed the cash payment via the establishment of a new term loan facility, issuance of senior notes and borrowings under its revolving credit facility. The

9


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

3.    Acquisition (Continued)


consideration associated with the common stock was $1,090,000 based on a stock price of $4.36 per share, representing the average closing price of Rite Aid common stock beginning two days prior to the announcement of the Acquisition on August 24, 2006 and ending two days after the announcement.

        The following unaudited pro forma consolidated financial data gives effect to the Acquisition as if it had occurred as of the beginning of the periods presented.

 
  Thirty-Nine Week
Periods Ended
 
 
  November 29,
2008
  December 1,
2007
 
 
  Actual
  Pro forma
 

Net revenues

  $ 19,581,701   $ 19,973,349  

Net loss

    (621,762 )   (184,344 )

Basic and diluted loss per share

  $ (0.77 ) $ (0.27 )

        The pro forma combined information assumes the acquisition of Brooks Eckerd occurred at the beginning of the period presented. These results have been prepared by combining the historical results of the Company and historical results of Brooks Eckerd. The pro forma financial data for the period presented include adjustments to reflect the incremental interest expense that results from the incurrence of the additional debt to finance the acquisition and additional depreciation and amortization expense resulting from the purchase price allocation. Pro forma results do not include any incremental cost savings that may result from the integration. Additionally, pro forma results have not been adjusted to reflect the divestiture of stores required by the FTC.

        The pro forma information does not purport to be indicative of the results that actually would have been achieved if the operations were combined during the period presented and is not intended to be a projection of future results or trends.

        In connection with the Acquisition, the Company entered into a transition services agreement with the Jean Coutu Group. Under the terms of this agreement, Jean Coutu Group provided certain information technology, network and support services to the Company. This agreement expired in September 2008. During the thirty-nine week periods ended November 29, 2008 and December 1, 2007, the Company recorded expense of $894 and $3,185, respectively, for services provided under this agreement.

4.    Reverse Stock Split

        On December 2, 2008, the Company's stockholders authorized a reverse stock split of its common stock at one of three ratios, 1-for-10, 1-for-15 or 1-for-20, to be selected by the Board of Directors. The objective of the reverse stock split is to ensure that Rite Aid regains compliance with the New York Stock Exchange (NYSE) share price listing rule and maintains its listing on the NYSE. Subject to NYSE rules, Rite Aid has until April 16, 2009 to regain compliance and currently continues to be listed and trade as usual on the NYSE. The exact timing for selection of the split ratio and the effective date

10


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

4.    Reverse Stock Split (Continued)


of the split will be determined by the Board based upon its evaluation as to when such action will be most advantageous to the Company and its stockholders, and the Board currently expects to make those decisions by the end of the Company's current fiscal year.

        The Company's stockholders also approved a decrease in the total number of authorized shares from 1,520,000,000 shares to 520,000,000. Upon effectiveness of the reverse stock split, the total authorized shares will be comprised of 500,000,000 shares of common stock, par value of $1.00 per share and 20,000,000 shares of preferred stock, par value of $1.00 per share. All relevant amounts in the accompanying condensed consolidated financial statements are presented on a pre-split basis since the Company's stock has not yet begun trading on a post-split basis.

5.    Convertible Preferred Stock

        On November 17, 2008, the remaining outstanding 2,416 shares of Series I Mandatory Convertible Preferred Stock ("Series I preferred stock") converted into common stock at a rate of 5.6561 shares of common stock for every share of Series I preferred stock.

6.    Loss Per Share

        Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company subject to anti-dilution limitations.

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Numerator for loss per share:

                         
 

Net loss

  $ (243,125 ) $ (84,846 ) $ (621,762 ) $ (126,810 )
 

Accretion of redeemable preferred stock

    (26 )   (26 )   (77 )   (77 )
 

Cumulative preferred stock dividends

    (5,591 )   (8,168 )   (17,081 )   (24,295 )
 

Preferred stock beneficial conversion

                (556 )
                   
 

Loss attributable to common stockholders, basic and diluted

  $ (248,742 ) $ (93,040 ) $ (638,920 ) $ (151,738 )
                   

Denominator:

                         
 

Basic and diluted weighted average shares

    840,554     785,512     833,855     699,453  
 

Basic and diluted loss per share:

  $ (0.30 ) $ (0.12 ) $ (0.77 ) $ (0.22 )
                   

11


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

6.    Loss Per Share (Continued)

        Due to their antidilutive effect, the following potential common shares have been excluded from the computation of diluted loss per share as of November 29, 2008 and December 1, 2007:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Stock options

    72,190     65,712     72,190     65,712  

Convertible preferred stock

    52,376     110,272     52,376     110,272  

Convertible debt

    61,045         61,045      
                   

    185,611     175,984     185,611     175,984  
                   

        Also excluded from the computation of diluted loss per share as of November 29, 2008 and December 1, 2007 are restricted shares of 6,876 and 9,601 which are included in shares outstanding.

7.    Lease Termination and Impairment Charges

        Lease termination and impairment charges consist of:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Impairment charges

  $ 67,588   $ 5,825   $ 74,853   $ 8,151  

Store and equipment lease exit charges

    34,047     16,011     114,869     34,302  
                   

  $ 101,635   $ 21,836   $ 189,722   $ 42,453  
                   

12


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

7.    Lease Termination and Impairment Charges (Continued)

Impairment charges

        Impairment charges include non-cash charges of $67,588 and $5,825 for the thirteen week periods ended November 29, 2008 and December 1, 2007, for the impairment of long-lived assets at 406 and 52 stores, respectively. Impairment charges include non-cash charges of $74,853 and $8,151 for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, for the impairment of long-lived assets at 544 and 75 stores, respectively. These amounts include the write-down of long-lived assets at stores that were assessed for impairment because of management's intention to relocate or close the store or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable. During the third quarter of fiscal 2009, the Company determined that a broader triggering event might have taken place within the Company's store base. Specifically, the broader impairment review was triggered by the increased severity of the economic turmoil and weakening U.S. economy during the quarter, which had a negative impact on the performance relating to a certain number of stores. This broader impairment analysis led to an additional charge for the third quarter of fiscal 2009 in the amount of $59,200. This amount represents management's estimate of impairment for the quarter, and additional amounts could be recorded at year end based upon information available at that time. This charge is primarily due to current and projected operating results at certain of the Company's Brooks Eckerd stores not being sufficient to cover the asset values at these stores.

Store and equipment lease exit charges

        During the thirteen week periods ended November 29, 2008 and December 1, 2007, the Company recorded charges for 29 and 16 stores to be closed or relocated under long term leases in each respective period. During the thirty-nine week periods ended November 29, 2008 and December 1, 2007, the Company recorded charges for 146 and 36 stores to be closed or relocated under long term leases in each respective period. Charges to close a store, which principally consist of lease termination costs, are recorded at the time the store is closed and all inventory is liquidated, pursuant to the guidance set forth in SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities". The Company calculates its liability for closed stores on a store-by-store basis. The calculation includes the discounted effect of future minimum lease payments and related ancillary costs, from the date of closure to the end of the remaining lease term, net of estimated cost recoveries that may be achieved through subletting properties or through favorable lease terminations. The Company evaluates these assumptions each quarter and adjusts the liability accordingly.

        The following table reflects the closed store charges that relate to new closures, changes in assumptions and interest accretion. The table for the thirteen and thirty-nine week periods ended December 1, 2007 also reflects the increase in the closed store reserve related to the acquisition of 183 closed stores from Jean Coutu USA as well as the additional liability related to 65 stores that Company management planned to close at that time as a result of the Acquisition. These liabilities represent the estimated fair value of the respective store lease commitments as of the date of the

13


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

7.    Lease Termination and Impairment Charges (Continued)


Acquisition and therefore were recorded as part of allocation of the purchase price of Jean Coutu USA.

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Balance—beginning of period

  $ 375,662   $ 326,250   $ 329,682   $ 195,205  
 

Provision for present value of noncancellable lease payments of closed stores

    15,097     5,353     94,176     16,722  
 

Changes in assumptions about future sublease income, terminations and changes in interest rates

    14,282     8,419     11,233     9,561  
 

Reversal of reserves for stores that management has determined will remain open

        (1,465 )       (1,465 )
 

Interest accretion

    5,327     3,933     14,593     10,067  
 

Leased properties of Jean Coutu USA closed or designated to be closed

        (1,304 )         134,868  
 

Cash payments, net of sublease income

    (21,635 )   (15,688 )   (60,951 )   (39,460 )
                   

Balance—end of period

  $ 388,733   $ 325,498   $ 388,733   $ 325,498  
                   

        The Company's revenues and income before income taxes for the thirteen and thirty-nine week periods ended November 29, 2008 and December 1, 2007 include results from stores that have been closed or are planned to be closed as of November 29, 2008. The revenue and operating losses of these stores for the periods are presented as follows:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2007
  December 1,
2007
 

Revenues

  $ 28,693   $ 201,563   $ 236,702   $ 621,183  

Loss from operations

    (4,616 )   (2,977 )   (40,832 )   (9,065 )

        Included in these stores' loss from operations for the thirteen week periods ended November 29, 2008 and December 1, 2007, are depreciation and amortization charges of $452 and $1,128 and closed store inventory liquidation charges of $1,894 and $1,681, respectively. Included in these stores' loss from operations for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, are depreciation and amortization charges of $3,616 and $3,594 and closed store inventory liquidation charges of $7,174 and $4,297, respectively. Loss from operations does not include any allocation of corporate level overhead costs. The above results are not necessarily indicative of the impact that these closures will have on revenues and operating results of the Company in the future, as the Company often transfers the business of a closed store to another Company store, thereby retaining a portion of these revenues. The amounts indicated above do not include the results of operations for stores closed related to discontinued operations.

14


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

8.    Income Taxes

        The Company recorded an income tax expense from continuing operations of $29,522 and an income tax benefit from continuing operations of $52,740 for the thirteen week periods ended November 29, 2008 and December 1, 2007 respectively, and income tax expense from continuing operations of $39,861 and income tax benefit from continuing operations of $92,210 for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively. The income tax expense for the thirteen and thirty-nine week period ended November 29, 2008 is primarily attributable to the increase of the valuation allowance on previously recorded federal and state net deferred tax assets. The provision for income taxes for the thirty-nine week period ended December 1, 2007 included a net benefit of $7,860 for the increase in deferred tax assets as a result of enacted state tax legislation as well as a net benefit of $5,974 for discrete items related to the recognition of previously unrecognized tax benefits. The discrete items associated with the previously unrecognized tax benefits included tax of $5,163 and related interest of $2,490 due to expiration of certain state statutes.

        Effective March 4, 2007, the Company adopted the provisions of FIN 48. As of November 29, 2008, and March 1, 2008 unrecognized tax benefits totaled $270,130 and $233,014, respectively. The Company recognizes interest and penalties related to tax contingencies as income tax expense. As of November 29, 2008 and March 1, 2008, the total amount of accrued income tax-related interest and penalties was $44,248 and $33,608, respectively.

        As of November 29, 2008 the total amount of unrecognized tax benefits that would be recorded as an adjustment to goodwill and not impact the effective tax rate in a future period was $238,025, which includes related interest and penalties. The remaining unrecognized tax benefits would impact the effective tax rate in a future period, although any impact on the effective rate may be mitigated by the valuation allowance that is maintained against the Company's net deferred tax assets. Upon the adoption of SFAS 141(Revised) which applies to fiscal year 2010, changes in income tax uncertainties recorded in a business combination will also affect income tax expense and will no longer impact goodwill. While it is expected that the amount of unrecognized tax benefits will change in the next twelve months, management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

        The Company is indemnified by Jean Coutu Group for certain tax liabilities incurred for all years ended up to and including June 4, 2007. Although the Company is indemnified by Jean Coutu Group, the Company remains the primary obligor to the tax authorities with respect to any tax liability arising for the years prior to the acquisition. Accordingly, as of November 29, 2008 the Company had a corresponding recoverable indemnification asset from Jean Coutu Group, included in the 'Other Assets' line of the Consolidated Balance Sheets, to reflect the indemnification for such liabilities.

        The Company files U.S. federal income tax returns as well as income tax returns in those states where it does business. The federal income tax returns are closed to examination by the Internal Revenue Service (IRS) through fiscal 2002. However, any net operating losses that were generated in these closed years may be subject to adjustment by the IRS upon utilization. The IRS is currently examining the consolidated U.S. income tax return for Brooks Eckerd for fiscal years 2004 and 2005. Additionally, the IRS is examining the consolidated U.S. income tax return for Rite Aid Corporation and subsidiaries for fiscal years 2006 and 2007. State income tax returns are generally subject to

15


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

8.    Income Taxes (Continued)


examination for a period of three to five years after filing of the respective return. However, as a result of reporting IRS audit adjustments, the Company has statutes open in some states from 1996.

        The valuation allowances as of November 29, 2008 and March 1, 2008 apply to the net deferred tax assets of the Company. Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109") requires a company to evaluate its deferred tax assets on a regular basis to determine if a valuation allowance against the net deferred tax assets is required. According to SFAS No. 109, a cumulative loss in recent years is significant negative evidence in considering whether deferred tax assets are realizable. Based on the negative evidence, SFAS 109 precludes relying on projections of future taxable income to support the recognition of deferred tax assets. The valuation allowance on federal and state net deferred tax assets was increased during the third quarter of 2009 and the fourth quarter of 2008. The increase for 2009 is related to the impact of the current economic conditions on 2009 results and the filing of the fiscal 2008 income tax returns. Accordingly, the Company had a valuation allowance against net deferred tax assets of $1,353,503 and $1,103,973 at November 29, 2008 and March 1, 2008, respectively.

9.    Discontinued Operations

        During the fourth quarter of fiscal 2008, the Company entered into agreements to sell the prescription files of 28 of its stores in the Las Vegas Nevada area. The Company owned four of these stores and the remaining stores were leased. The Company has assigned the lease rights of 17 of these stores to other entities and closed the remaining stores. The Company has sold one of the owned stores and plans to sell the remaining three owned stores. The sale and transfer of the prescription files has been completed and the inventory at the closed stores has been liquidated.

        The Company has presented the operating results of Las Vegas as a discontinued operation in the statement of operations for the thirty-nine week period ended November 29, 2008 and the thirteen and thirty-nine week periods ended December 1, 2007. The following amounts have been segregated from continuing operations and included in discontinued operations:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Revenues

  $ 25,632   $ 267   $ 78,535  

Costs and expenses:

                   
 

Cost of goods sold

    18,838     1,652     58,126  
 

Selling, general and administrative expenses

    8,873     1,936     25,751  
 

Loss on sale of assets

        48      
               

Total costs and expenses

    27,711     3,636     83,877  
               

Loss from discontinued operations before income taxes

    (2,079 )   (3,369 )   (5,342 )

Income tax benefit

    (728 )       (1,870 )
               
 

Net loss from discontinued operations

  $ (1,351 ) $ (3,369 ) $ (3,472 )
               

16


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

9.    Discontinued Operations (Continued)

        The assets and liabilities of the divested stores as of November 29, 2008 and March 1, 2008 are not significant and have not been segregated in the consolidated balance sheets.

10.    Accounts Receivable

        The Company maintains securitization agreements with several multi-seller asset-backed commercial paper vehicles ("CPVs"). Under the terms of the securitization agreements, the Company sells substantially all of its eligible third party pharmaceutical receivables to a bankruptcy remote Special Purpose Entity ("SPE") and retains servicing responsibility. The assets of the SPE are not available to satisfy the creditors of any other person, including any of the Company's affiliates. These agreements provide for the Company to sell, and for the SPE to purchase these receivables. The SPE then transfers an interest in these receivables to various CPVs.

        The securitization agreement expires in September of 2010. Under the terms of the securitization agreement, the CPV's enter into commitments to purchase of no longer than 364 days. The CPV's current commitments to purchase expire on January 15, 2009. The securitization agreement also provides for a backstop credit facility that is supported by the banks under the securitization agreement and that the Company can access if the CPV's do not renew their commitment to purchase.

        Under the terms of the securitization agreements, the total amount of interest in receivables that can be transferred to the CPVs is $650,000. The amount of transferred receivables outstanding at any one time is dependent upon a formula that takes into account such factors as default history, obligor concentrations and potential dilution ("Securitization Formula"). Adjustments to this amount can occur, at the discretion of the CPV's, on a weekly basis. At November 29, 2008 and March 1, 2008, the total outstanding receivables that have been transferred to CPVs were $545,000 and $435,000, respectively. The following table details receivable transfer activity for the thirteen and thirty-nine week periods ended November 29, 2008 and December 1, 2007:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Average amount of outstanding receivables transferred

  $ 512,363   $ 320,879   $ 476,429   $ 332,637  

Total receivable transfers

  $ 1,950,000   $ 1,233,000   $ 5,294,000   $ 3,673,000  

Collections made by the Company as part of the servicing arrangement on behalf of the CPVs

  $ 1,905,000   $ 1,123,000   $ 5,184,000   $ 3,623,000  

        At November 29, 2008 and March 1, 2008, the Company retained an interest in the eligible third party pharmaceutical receivables not transferred to the CPVs of $449,061 and $493,833, respectively, inclusive of the allowance for uncollectible accounts, which was included in accounts receivable, net, on the consolidated balance sheet.

17


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

10.    Accounts Receivable (Continued)

        On September 16, 2008, the securitization agreement was amended. As a result of the amendment, the CPV's extended their commitment to purchase under the securitization agreement to January 15, 2009. Subsequent to January 15, 2009, should any of the CPV's fail to renew or extend their commitment under these agreements, the Company continues to have access to the backstop credit facility to provide liquidity to the Company. If the Company has to draw on the backstop facility, the rate will be LIBOR plus 5.50%. This rate will be applied to the entire facility commitment of $650,000. Amounts available under the backstop facility would be dependent upon a formula that takes into account such factors as default history, obligor concentrations and potential dilution. Adjustments to the formula would be at the discretion of the banks.

        The amendment to the securitization agreement also modified the program and liquidity fees. The program fee is calculated as commercial paper borrowing rates (which often approximate LIBOR) plus 1.25% applied to receivables transferred to the CPV's. The liquidity fee is calculated as 1.50% of the total securitization agreement commitment of $650,000. The program and the liquidity fees are recorded as a component of selling, general and administrative expenses. Program and liquidity fees for the thirteen week periods ended November 29, 2008 and December 1, 2007 were $7,613 and $6,310, respectively. Program and liquidity fees for the thirty-nine week periods ended November 29, 2008 and December 1, 2007 were $16,921 and $17,289, respectively.

        Rite Aid Corporation guarantees certain performance obligations of its affiliates under the securitization agreements, which includes the continued servicing of such receivables, but does not guarantee the collectibility of the receivables and obligor creditworthiness.

        Proceeds from the collections under the receivables securitization agreements are submitted to an independent trustee on a daily basis. The trustee withholds any cash necessary to (1) fund amounts owed to the CPVs as a result of such collections and (2) fund the CPVs when the Securitization Formula indicates a lesser amount of outstanding receivables transferred is warranted. The remaining collections are swept to the Company's corporate concentration account. At November 29, 2008 and March 1, 2008, the Company had $2,724 and $3,277 of cash, respectively, that is restricted for the payment of trustee fees.

        The Company has determined that the transactions meet the criteria for sales treatment in accordance with SFAS No. 140 "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities". Additionally, the Company has determined that it does not hold a variable interest in the CPVs, pursuant to the guidance in FIN 46R, "Consolidation of Variable Interest Entities", and therefore has determined that the de-recognition of the transferred receivables is appropriate.

11.    Sale Leaseback Transactions

        During the thirty-nine week period ended November 29, 2008, the Company sold a total of 72 owned properties to independent third parties. Net proceeds from these sales were $192,819. Concurrent with these sales, the Company entered into agreements to lease the stores back from the

18


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

11.    Sale Leaseback Transactions (Continued)


purchasers over minimum lease terms of 20 years. The Company accounted for 64 of these leases as operating leases and eight are being accounted for under the financing method as these lease agreements contain a clause that allows the buyer to force the Company to repurchase the property under certain conditions. Gains on these transactions of $3,777 have been deferred and are being recorded over the related minimum lease terms. Losses of $411 which relate to certain stores in these transactions, were recorded as losses on the sale of assets.

        During the thirty-nine week period ended December 1, 2007, the Company sold a total of five owned properties to independent third parties. Net proceeds from these sales were $20,757. Concurrent with these sales, the Company entered into agreements to lease the stores back from the purchasers over minimum lease terms of 20 years. The Company accounted for all of these leases as operating leases. A gain of $1,928 was deferred and is being recorded over the minimum term of these leases.

12.    Goodwill and Other Intangibles

        The Company accounts for goodwill under the guidance set forth in SFAS No. 142, which specifies that goodwill should not be amortized. The Company's policy is to evaluate goodwill for impairment on an annual basis at the end of its fiscal year or more frequently if events or circumstances occur that would indicate a reduction in the fair value of the Company. On November 29, 2008, the carrying value of the Company's net assets was $1,111,179 and the market capitalization of the Company's outstanding shares, assuming conversion of outstanding preferred shares, was $474,026. Accordingly, management performed an interim goodwill impairment test in accordance with SFAS 142. Management has calculated the estimated fair value of the Company as that amount that would be received to sell the Company as a whole in an orderly transaction between market participants as of November 29, 2008. Management arrived at the estimated fair value by preparing a discounted cash flow analysis using updated forward looking projections of the Company's estimated future operating results. Based on the results of the discounted cash flow analysis management has concluded that the Company's fair value exceeds its carrying value at November 29, 2008 and that goodwill is not impaired. The Company also considered as an indicator of market value the market value of its common stock as of November 29, 2008. However, given the extreme volatility in the stock market during the quarter ended November 29, 2008, as well as the impact that the credit crisis and the recession had on the equity markets during that period, and the fact that, after consideration of a control premium, the Company's stock only started to trade below book value during the third quarter, management concluded that it was appropriate to place more reliance on fair value as calculated by the Company's discounted cash flow model in evaluating goodwill impairment as of November 29, 2008. Management's continued reliance on its discounted cash flow model may not be appropriate in the future if the Company's market capitalization continues to be less than the carrying value of the Company's net assets. If we determine that we have not passed the step one test of SFAS 142, we believe that the entire recorded amount of goodwill would be impaired under the step two test of SFAS 142.

19


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

12.    Goodwill and Other Intangibles (Continued)

        The significant assumptions used by management in its discounted cash flow analysis include: net income, the discount rate used to present value future cash flows, and capital expenditures. Net income assumptions include sales growth assumptions which are based on the Company's historical trends, including the impact of the converted Brooks Eckerd stores and normal prescription file purchases, but do not include the impact of any new stores or relocated stores. Also included in net income are gross margin and SG&A growth assumptions which are based on the historical relationship of those measures compared to sales and include certain cost cutting initiatives which management began to undertake in the third quarter of 2009. The Company's discount rate used is a "market participant" weighted average cost of capital ("WAAC") and was 10.5% at November 29, 2008. The Company assumed a level of capital expenditures of approximately $350,000 to $370,000 per year, which includes the cost of normal prescription file purchases. Management has performed a sensitivity analysis on its significant assumptions and has determined that a reasonable, negative change in its assumptions, as follows, would not impact its conclusion: reduce net income by 10%, increase the WAAC by 100 basis points, or increase capital expenditures by 10%.

        The Company's intangible assets other than goodwill are finite-lived and amortized over their useful lives. Following is a summary of the Company's amortizable intangible assets as November 29, 2008 and March 1, 2008.

 
  November 29, 2008   March 1, 2008
 
  Gross
Carrying
Amount
  Accumulated
Amortization
  Remaining
Weighted
Average
Amortization
Period
  Gross
Carrying
Amount
  Accumulated
Amortization
  Remaining
Weighted
Average
Amortization
Period

Favorable leases and other

  $ 727,140   $ (275,927 ) 11 years   $ 738,855   $ (240,079 ) 12 years

Prescription files

    1,207,375     (570,865 ) 8 years     1,152,620     (464,069 ) 9 years
                         

Total

  $ 1,934,515   $ (846,792 )     $ 1,891,475   $ (704,148 )  
                         

        Also included in other non-current liabilities as of November 29, 2008 and March 1, 2008 are unfavorable lease intangibles with a net carrying amount of $130,360 and $147,035, respectively. These intangible liabilities are amortized over their remaining lease terms.

        Amortization expense for these intangible assets and liabilities was $50,691 and $151,756 for the thirteen and thirty-nine week periods ended November 29, 2008. Amortization expense for these intangible assets and liabilities was $53,209 and $112,884 for the thirteen and thirty-nine week periods ended December 1, 2007. The anticipated annual amortization expense for these intangible assets and liabilities is 2009—$193,751; 2010—$178,680; 2011—$165,079; 2012—$131,179; and 2013—$106,420.

20


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

13.    Indebtedness and Credit Agreements

        Following is a summary of indebtedness and lease financing obligations at November 29, 2008 and March 1, 2008:

 
  November 29,
2008
  March 1,
2008
 

Secured Debt:

             
 

Senior secured revolving credit facility due September 2010

  $ 1,146,000   $ 849,000  
 

Senior secured credit facility term loan due September 2010

    145,000     145,000  
 

Senior secured credit facility term loan due June 2014

    1,099,475     1,105,000  
 

Senior secured credit facility term loan due July 2016 ($350,000 face value less unamortized discount of $33,028)

    316,972      
 

7.5% senior secured notes due January 2015

        200,000  
 

10.375% senior secured notes due July 2016 ($470,000 face value less unamortized discount of $42,393)

    427,607      
 

7.5% senior secured notes due March 2017

    500,000     500,000  
 

Other secured

    4,357     2,740  
           

    3,639,411     2,801,740  

Guaranteed Unsecured Debt:

             
 

8.625% senior notes due March 2015

    500,000     500,000  
 

9.375% senior notes due December 2015 ($410,000 face value less unamortized discount of $4,930 and 5,458)

    405,070     404,542  
 

9.5% senior notes due June 2017 ($810,000 face value less unamortized discount of $11,057 and 12,033)

    798,943     797,967  
           

    1,704,013     1,702,509  

Unsecured Unguaranteed Debt:

             
 

6.125% fixed-rate senior notes due December 2008

        150,000  
 

8.125% senior notes due May 2010

    11,117     358,500  
 

9.25% senior notes due June 2013

    6,015     148,739  
 

6.875% senior debentures due August 2013

    184,773     184,773  
 

8.5% convertible notes due May 2015

    158,000      
 

7.7% notes due February 2027

    295,000     295,000  
 

6.875% fixed-rate senior notes due December 2028

    128,000     128,000  
           

    782,905     1,265,012  

Lease financing obligations

    221,324     216,263  
           

Total debt

    6,347,653     5,985,524  

Current maturities of long-term debt and lease financing obligations

    (42,065 )   (185,609 )
           

Long-term debt and lease financing obligations, less current maturities

  $ 6,305,588   $ 5,799,915  
           

21


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

13.    Indebtedness and Credit Agreements (Continued)

Refinancing Transactions

        In July 2008, pursuant to a tender offer and consent solicitation, the Company repurchased substantially all of the outstanding amounts of its 8.125% senior secured notes due May 2010, its 7.5% senior secured notes due January 2015 and its 9.25% senior notes due June 2013. This transaction was done because these notes had restrictions on the incurrence of liens securing the secured debt that prohibited the Company from fully drawing on its revolving credit facility under certain circumstances. The remaining outstanding amounts of such series no longer contain such restrictions and are no longer secured or guaranteed. The Company recorded a loss on debt modification related to these transactions of $36,558 in the thirteen week period ended August 30, 2008.

        These transactions were financed via the issuance of a new senior secured term loan (the "Tranche 3 Term Loan") of $350,000 under the Company's existing senior secured credit facility and the issuance of a $470,000 aggregate principal amount of 10.375% senior secured notes due July 2016. The Tranche 3 Term Loan was issued at a discount of 90% of par. The Tranche 3 Term Loan matures on June 4, 2014 and bears interest at LIBOR (with a minimum LIBOR rate of 3.00%) plus 3.00%, if the Company chooses to make LIBOR borrowings, or at Citibank's base rate (with a minimum base rate of 4.00%) plus 2.00%. The Company must make mandatory prepayments of the Tranche 3 Term Loan with the proceeds of asset dispositions (subject to certain limitations), with a portion of any excess cash flow generated by the Company and with the proceeds of certain issuances of equity and debt (subject to certain exceptions). If at any time there is a shortfall in the Company's borrowing base under the Company's revolving credit facility, prepayment of the Tranche 3 Term Loan may also be required.

        The Company's $470,000 10.375% senior secured notes due July 2016 are unsecured unsubordinated obligations of Rite Aid Corporation and rank equally in right of payment with all other unsubordinated indebtedness. The Company's obligations under the notes are guaranteed, subject to certain limitations, by subsidiaries that guarantee the obligations under its senior secured credit facility. The guarantees are secured by shared second priority liens with holders of our 7.5% senior secured notes due 2017. The indenture that governs the 10.375% senior secured notes due 2016 contains covenant provisions that, among other things, include limitations on the Company's ability to pay dividends, make investments or other restricted payments, incur debt, grant liens, sell assets and enter into sale-leaseback transactions. The senior 10.375% secured notes due July 2016 were issued at a discount of 90.588% of par.

        In May 2008, the Company issued $158,000 of 8.5% convertible notes due May 2015. These notes are unsecured and are effectively junior to the secured debt of the Company. The notes are convertible, at the option of the holder, into shares of the Company's common stock at a conversion price of $2.59 per share, subject to adjustments to prevent dilution, at any time. Proceeds from the issuance of these notes were used to fund the redemption of the Company's 6.125% notes due December 2008. The Company recorded a loss on debt modification of $3,347 related to the early

22


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

13.    Indebtedness and Credit Agreements (Continued)


redemption of the 6.125% notes due 2008, which included payment of a make whole premium to the noteholders and unamortized debt issue costs on the notes.

Credit Facility

        The Company has a senior secured credit facility that includes a $1,750,000 revolving credit facility. Borrowings under the revolving secured credit facility currently bear interest at LIBOR plus 1.75%, if the Company chooses to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. The interest rate can fluctuate depending upon the amount of the revolver availability, as specified in the senior secured credit facility. The Company is required to pay fees of 0.25% per annum on the daily unused amount of the revolving credit facility. The amounts drawn on the revolving credit facility become due and payable in September 2010.

        The Company's ability to borrow under the revolving credit facility is based upon a specified borrowing base consisting of inventory and prescription files. At November 29, 2008, the Company had $1,146,000 of borrowings outstanding under the revolving credit facility. At November 29, 2008, the Company also had letters of credit outstanding against the revolving credit facility of $174,303, which gave the Company additional borrowing capacity of $429,697.

        In November 2006, the Company entered into an amendment of its senior secured credit facility and borrowed $145,000 under a senior secured term loan (the "Tranche 1 Term Loans"). The Tranche 1 Term Loans currently bear interest at LIBOR plus 1.75%, if the Company chooses to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. The interest rate can fluctuate depending on the amount of availability under the Company's revolving credit facility, as specified in the senior secured credit facility. The amounts outstanding under the Tranche 1 Term Loans become due and payable on September 30, 2010, or earlier, if there is a shortfall in the Company's borrowing base under its revolving credit facility.

        On June 4, 2007, the Company amended its senior secured credit facility to establish a new senior secured term loan (the "Tranche 2 Term Loans") in the aggregate principal amount of $1,105,000 and borrowed the full amount thereunder. The Tranche 2 Term Loans will mature on June 4, 2014 and currently bears interest at LIBOR plus 1.75%, if the Company chooses to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. The Company must make mandatory prepayments of the Tranche 2 Term Loans with the proceeds of asset dispositions (subject to certain limitations), with a portion of any excess cash flow generated by the Company and with the proceeds of certain issuances of equity and debt (subject to certain exceptions). If at any time there is a shortfall in the Company's borrowing base under the Company's revolving credit facility, prepayment of the Tranche 2 Term Loans may also be required.

        The senior secured credit facility allows the Company to have outstanding, at any time, up to $1,500,000 in secured second priority debt and unsecured debt in addition to borrowings under the

23


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

13.    Indebtedness and Credit Agreements (Continued)


senior secured credit facility and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt and unsecured debt shall mature or require scheduled payment of principal prior to three months after September 30, 2014. The senior secured credit facility allows the Company to incur an unlimited amount of unsecured debt with a maturity beyond three months after September 30, 2014; however, other debentures limit the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence of said debt. The senior secured credit facility also allows for the repurchase of any debt with a maturity on or before June 4, 2014, and for the voluntary repurchase of debt with a maturity after June 4, 2014, if the Company maintains availability on the revolving credit facility of at least $100,000.

        The senior secured credit facility contains covenants, which place restrictions on the incurrence of debt beyond the restrictions described above, the payments of dividends, mergers and acquisitions and the granting of liens. The senior secured credit facility also requires the Company to maintain a minimum fixed charge coverage ratio, but only if availability on the revolving credit facility is less than $100,000.

        The senior secured credit facility provides for events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if the Company fails to make any required payment on debt having a principal amount in excess of $50,000 or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity of such debt.

        Substantially all of Rite Aid Corporation's wholly-owned subsidiaries guarantee the obligations under the senior secured credit facility. The subsidiary guarantees of the senior secured credit facility are secured by a first priority lien on, among other things the inventory and prescription files of the subsidiary guarantors. Rite Aid Corporation is a holding company with no direct operations and is dependent upon dividends, distributions and other payments from its subsidiaries to service payments due under the senior secured credit facility. The 7.5% senior secured notes due 2017 and the 10.375% senior secured notes due 2016 are guaranteed by substantially all of the Company's wholly-owned subsidiaries, which are the same subsidiaries that guarantee the senior secured credit facility and are secured on a second priority basis by the same collateral as the senior secured credit facility. The 8.625% senior notes due 2015, the 9.375% senior notes due 2015 and the 9.5% senior notes due 2017 are also guaranteed, on an unsecured basis, by substantially all of the same subsidiaries.

        The subsidiary guarantees related to the Company's senior secured credit facility and the guaranteed indentures are unconditional and joint and several. Also, the parent company has no independent assets or operations, and subsidiaries not guaranteeing the credit facility and applicable indentures are minor. Accordingly, condensed consolidating financial information for the parent and subsidiaries is not presented.

24


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

13.    Indebtedness and Credit Agreements (Continued)

Other

        The indentures that govern the Company's secured and guaranteed unsecured notes contain restrictions on the amount of additional secured and unsecured debt that can be incurred by the Company. As of November 29, 2008, the amount of additional secured and unsecured debt that could be incurred under these indentures was $812,464.

        The aggregate annual principal payments of long-term debt for the remainder of fiscal 2009 and thereafter are as follows: 2009—$3,873; 2010—$16,588; 2011—$1,316,855; 2012—$14,765; 2013—$14,764 and $4,759,484 in 2014 and thereafter.

14.    Stock Option and Stock Awards

        Effective March 5, 2006, the Company adopted SFAS No. 123 (R), "Share-Based Payment" using the modified prospective transition method. Expense is recognized over the requisite service period of the award, net of an estimate for the impact of forfeitures. Total share-based compensation expense for the thirty-nine week periods ended November 29, 2008 and December 1, 2007 was $25,921 and $29,833, respectively.

        The total number and type of grants and the related weighted average fair value for the thirty-nine week periods are as follows:

 
  November 29, 2008   December 1, 2007  
 
  Shares   Weighted
Average
Fair
Value
  Shares   Weighted
Average
Fair
Value
 

Stock options granted

    13,483   $ 0.44     10,446   $ 3.24  

Stock awards granted

    2,607   $ 0.95     7,042   $ 6.07  
                       
 

Total awards

    16,090           17,488        
                       

        Stock options granted vest, and are subsequently exercisable in equal annual installments over a four-year period for employees. Non-employee director options granted vest, and are subsequently exercisable in equal annual installments over a three-year period. Stock awards granted vest in equal annual installments over a three year period.

25


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

14.    Stock Option and Stock Awards (Continued)

        The Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing model. The following assumptions were used in the Black-Scholes-Merton option pricing model:

 
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
 

Expected stock price volatility

    50 %   52 %

Expected dividend yield

    0 %   0 %

Risk-free interest rate

    2.9 %   5.0 %

Expected option life

    5.25 years     5.5 years  

        As of November 29, 2008, there was $25,918 of total unrecognized pre-tax compensation costs related to unvested stock options, net of estimated forfeitures. These costs are expected to be recognized over a weighted average period of 2.4 years. As of November 29, 2008, there was $18,996 of total unrecognized pre-tax compensation costs related to unvested restricted stock grants, net of estimated forfeitures. These costs are expected to be recognized over a weighted average period of 1.6 years.

15.    Retirement Plans

        Net periodic pension expense recorded in the thirteen and thirty-nine week periods ended November 29, 2008 and December 1, 2007, for the Company's defined benefit plans includes the following components:

 
  Defined Benefit
Pension Plan
  Nonqualified Executive Retirement Plans   Defined Benefit
Pension Plan
  Nonqualified Executive Retirement Plans  
 
  Thirteen Week Period Ended   Thirty-Nine Week Period Ended  
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 

Service cost

  $ 572   $ 724   $ 13   $ 12   $ 2,114   $ 2,440   $ 38   $ 36  

Interest cost

    1,397     1,354     300     285     4,305     4,106     900     861  

Expected return on plan assets

    (1,289 )   (1,246 )           (3,979 )   (3,790 )        

Amortization of unrecognized net transition obligation

                21                 65  

Amortization of unrecognized prior service cost

    250     249             748     747          

Amortization of unrecognized net loss

    30     164     5     24     246     634     15     72  
                                   

Net pension expense

  $ 960   $ 1,245   $ 318   $ 342   $ 3,434   $ 4,137   $ 953   $ 1,034  
                                   

26


Table of Contents


RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

For the Thirteen and Thirty-Nine Week Periods Ended November 29, 2008 and December 1, 2007

(Dollars and share information in thousands, except per share amounts)

(unaudited)

15.    Retirement Plans (Continued)

        During the thirteen and thirty-nine week periods ended November 29, 2008 the Company contributed $454 and $1,315, respectively, to the Nonqualified Executive Retirement Plan. During the thirty-nine week period ended November 29, 2008 the Company contributed $1,174 to the Defined Benefit Pension Plan. During the remainder of fiscal 2009, the Company expects to contribute $438 to the Nonqualified Executive Retirement Plans.

16.    Commitments and Contingencies

        The Company is subject from time to time to lawsuits and governmental investigations arising in the ordinary course of business, including employment related lawsuits arising from alleged violations of certain state and federal laws. Some of these suits purport to have been determined to be class or collective actions and/or seek substantial damages. In the opinion of the Company's management, these matters are adequately covered by insurance or, if not so covered, are without merit or are of such nature or involve amounts that would not have a material adverse effect on the Company's financial condition, results of operations or cash flows if decided adversely.

        The Company has been contacted by the U.S. Department of Justice, representing the Drug Enforcement Administration concerning certain alleged civil violations of the recordkeeping and reporting requirements of the Controlled Substances Act. The Company is in continuing discussions with the government on resolving this matter. The Company has reached an agreement to settle this matter for $5,000, which has been reserved against this potential liability. The Company has also agreed, among other things, to maintain an existing compliance program designed to detect and prevent the diversion of controlled substances as required under the Controlled Substances Act.

27


Table of Contents

ITEM 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

        Net loss for the thirteen week period ended November 29, 2008 was $243.1 million compared to $84.8 million for the thirteen week period ended December 1, 2007. The increase in net loss was primarily driven by an increase in lease termination and impairment charges, an increase in LIFO expense, and an income tax expense of $29.5 million for the thirteen week period ended November 29, 2008, compared to an income tax benefit of $52.7 million for the thirteen week period ended December 1, 2007. These items were partially offset by an improvement in gross margin rate (after adjusting for the impact of the increased LIFO expense) and an improvement in selling, general and administrative expenses ("SG&A") as a percentage of sales. These items are described in further detail in the following sections.

        Net loss for the thirty-nine week period ended November 29, 2008 was $621.8 million compared to net loss of $126.8 million for the thirty-nine week period ended December 1, 2007. The operating results for the thirty-nine week period ended December 1, 2007 include the operating results of Brooks Eckerd for the twenty-six week period ended December 1, 2007. Operating results were negatively impacted by an increase in SG&A as a percentage of revenues, an increase in store closing and impairment charges, an increase in interest expense, a loss on debt modification related to the refinancing transactions that occurred in May and July of 2008 and an income tax expense of $39.9 million in the thirty-nine week period ended November 29, 2008, compared to an income tax benefit of $92.2 million in the thirty-nine week period ended December 1, 2007. These items are described in further detail in the following sections.

        For a discussion of risks related to our financial condition, operations and industry, refer to "Risk Factors" included herein and in our fiscal 2008 10-K and our 10-Q for the twenty-six weeks ended August 30, 2008, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our fiscal 2008 10-K.

Recent Events

        On December 2, 2008, our stockholders authorized a reverse stock split of our common stock at one of three ratios, 1-for-10, 1-for-15 or 1-for-20, to be selected by the Board of Directors. The objective of the reverse stock split is to ensure that Rite Aid regains compliance with the New York Stock Exchange (NYSE) share price listing rule and maintains its listing on the NYSE. Subject to NYSE rules, Rite Aid has until April 16, 2009 to regain compliance and currently continues to be listed and trade as usual on the NYSE. The exact timing for selection of the split ratio and the effective date of the split will be determined by the Board based upon its evaluation as to when such action will be most advantageous for Rite Aid and our stockholders. The Board currently expects to make those decisions by the end of our current fiscal year.

28


Table of Contents

Results of Operations

    Revenues and Other Operating Data

 
  Thirteen Week Period Ended   Thirty-Nine Week Period Ended  
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 
 
  (dollars in thousands)
 

Revenues

  $ 6,468,601   $ 6,497,912   $ 19,581,701   $ 17,502,024  

Revenue (decline) growth

    (0.5 )%   51.3 %   11.9 %   36.0 %

Same store sales growth

    1.4 %   0.7 %   1.1 %   1.4 %

Pharmacy sales (decline) growth

    (1.4 )%   60.6 %   12.1 %   42.1 %

Same store pharmacy sales growth

    1.0 %   1.2 %   0.7 %   1.8 %

Pharmacy sales as a % of total sales

    67.9 %   68.3 %   67.5 %   67.0 %

Third party sales as a % of total pharmacy sales

    96.4 %   96.0 %   96.3 %   95.9 %

Front-end sales growth

    0.4 %   33.9 %   9.9 %   24.9 %

Same store front-end sales growth (decline)

    2.3 %   (0.4 )%   2.0 %   0.6 %

Front-end sales as a % of total sales

    32.1 %   31.7 %   32.5 %   33.0 %

Store data:

                         
 

Total stores (beginning of period)

    4,930     5,142     5,059     3,333  
 

New stores

    13     12     26     29  
 

Store acquisitions, net

            9     1,862  
 

Closed stores

    (29 )   (65 )   (180 )   (135 )
 

Total stores (end of period)

    4,914     5,089     4,914     5,089  
 

Relocated stores

    23     21     46     36  
 

Remodeled stores

    11     93     70     128  

    Revenues

        Revenues declined 0.5% in the thirteen week period ended November 29, 2008, due to a reduction in the store base resulting from the closure of unprofitable stores and stores that were in close proximity, as well as the same store sales trends described below. Revenue growth was 11.9% in the thirty-nine week period ended November 29, 2008, driven primarily by the acquisition of the Brooks Eckerd stores on June 4, 2007. Same store sales trends, which include the results of the Brooks Eckerd stores in the thirty-nine week period ended November 29, 2008, are described in the following paragraphs.

        Pharmacy same store sales improved 1.0% in the thirteen week period ended November 29, 2008. Increases in price per prescription were offset by a same store prescription decline of 1.0%, driven by script count declines in the Brooks Eckerd stores and increased generic penetration. Pharmacy same store sales for the core Rite Aid stores increased 3.0% while pharmacy same store sales at the Brooks Eckerd stores declined 2.6%. However, this trend has improved over the decline of 4.6% in pharmacy same store sales in the Brooks Eckerd stores in the thirteen week period ended August 30, 2008. We believe that pharmacy comparable sales trends at the Brooks Eckerd stores will continue to improve as a result of our focus on prescription file buys, our senior loyalty program, our new Rite Aid Rx savings card, our courtesy refill program and our pharmacy marketing and promotional programs to get back lost customers.

        Pharmacy same store sales increased by 0.7% in the thirty-nine week period ended November 29, 2008. Increases in price per prescription were offset by a same store prescription decline, driven by script count declines in the Brooks Eckerd stores and increased generic penetration. Also impacting the negative script trend were switches of prescriptions to over-the-counter products and the overall economic environment.

29


Table of Contents

        Front-end same store sales increased by 2.3% and 2.0% in the thirteen and thirty-nine week periods ended November 29, 2008, respectively. The increase was primarily due to strong performance in our consumable and over-the-counter categories and improvement in our private brand penetration. These items were offset somewhat by weakness in the overall economic environment which had a negative impact on seasonal sales and decreases in photo sales, which were due to the continuing trend of consumers printing fewer images as well as the costs of the conversion of our photo technology to FUJI digital equipment. Front-end same store sales for the core Rite Aid stores increased 1.9% in the thirteen week period ended November 29, 2008, while front-end same store sales for the Brooks Eckerd stores increased 3.7% for the thirteen week period ended November 29, 2008.

        We include in same store sales all stores that have been open or owned at least one year. Relocated stores are not included in the same store sales for one year. Stores in liquidation are considered closed.

    Costs and Expenses

 
  Thirteen Week Period Ended   Thirty-Nine Week Period Ended  
 
  November 29, 2008   December 1, 2007   November 29, 2008   December 1, 2007  
 
  (dollars in thousands)
 

Cost of goods sold

  $ 4,743,089   $ 4,754,057   $ 14,269,769   $ 12,752,779  

Gross profit

    1,725,512     1,743,855     5,311,932     4,749,245  

Gross margin rate

    26.7 %   26.8 %   27.1 %   27.1 %

Selling, general and administrative expenses

    1,711,873     1,730,053     5,285,478     4,591,843  

Selling, general and administrative expenses as a percentage of revenues

    26.5 %   26.6 %   27.0 %   26.2 %

Lease termination and impairment charges

    101,635     21,836     189,722     42,453  

Interest expense

    126,615     130,306     363,420     322,281  

Loss on debt modifications and retirements, net

            39,905     12,900  

Loss (gain) on sale of assets, net

    (1,008 )   (2,105 )   11,939     (4,684 )

    Cost of Goods Sold

        Gross margin rate was 26.7% for the thirteen week period ended November 29, 2008 compared to 26.8% for the thirteen week period ended December 1, 2007. The increase in LIFO charges discussed below offset an improvement in FIFO gross margin rate. Front-end gross margin rate on a FIFO basis improved due to a decrease in shrink expense, improved markdown control and improved billing margins, offset slightly by deterioration in the photo gross margin. The decrease in photo gross margin is due to lower revenues and rate, which were both negatively impacted by the migration of consumers from one hour photo to digital. Pharmacy gross margin rate on a FIFO basis improved due to an improvement in generic mix, offset somewhat by a decrease in reimbursement rates. Distribution costs improved due to better labor control, reductions in volume due to lower inventory and a decline in fuel costs.

        Gross margin rate was 27.1% for the thirty-nine week period ended November 29, 2008 compared to 27.1% for the thirty-nine week period ended December 1, 2007. The improvement in pharmacy gross margin rate, which was driven by an increase in the percentage of generic drugs sold and a lower cost of generics, was offset by a reduction in front end gross margin rate due to less vendor promotional support, an increase in distribution costs, which was caused by an increase in fuel prices, and an increase in LIFO expense.

30


Table of Contents

        We use the last-in, first-out (LIFO) method of inventory valuation. Cost of sales includes LIFO charges of $59.8 million and $90.0 million for the thirteen and thirty-nine week periods ended November 29, 2008 versus LIFO charges of $16.0 million and $41.4 million for the thirteen and thirty-nine week periods ended December 1, 2007. We finalize our inventory valuation calculation annually during our fourth fiscal quarter, when inflation rate and inventory levels are known. However, due to increases in product costs, we are anticipating higher LIFO expenses for the year than what was originally estimated and have therefore recorded higher LIFO expense in the thirteen week period ended November 29, 2008.

    Selling, General and Administrative Expenses

        SG&A as a percentage of revenues was 26.5% in the thirteen week period ended November 29, 2008 compared to 26.6% in the thirteen week period ended December 1, 2007. The improvement in SG&A as a percentage of revenues is due to decreased integration expense, a reduction in store and administrative labor costs, a reduction in workers compensation and general liability insurance expenses and a reduction in non-union medical expenses. These items were partially offset by increases in union benefit costs, depreciation expense and occupancy expense.

        SG&A as a percentage of revenues was 27.0% in the thirty-nine week period ended November 29, 2008 compared to 26.2% in the thirty-nine week period ended December 1, 2007. The increase in SG&A as a percentage of revenues is primarily due to an increase in depreciation and amortization expense related primarily to increased intangible assets resulting from the allocation of the purchase price of Brooks Eckerd, an increase in rent and occupancy expense in new and relocated stores, the sale and leaseback of owned stores and inflation in salaries and benefit costs. These items were somewhat offset by a decrease in intergration expenses and advertising costs.

    Lease Termination and Impairment Charges

        Lease termination and impairment charges consist of:

 
  Thirteen Week
Period Ended
  Thirty-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 
 
  (dollars in thousands)
 

Impairment charges

  $ 67,588   $ 5,825   $ 74,853   $ 8,151  

Store and equipment lease exit charges

    34,047     16,011     114,869     34,302  
                   

  $ 101,635   $ 21,836   $ 189,722   $ 42,453  
                   

         Impairment Charges:     Impairment charges include non-cash charges of $67.6 million and $5.8 million in the thirteen week periods ended November 29, 2008 and December 1, 2007, respectively, for the impairment of long-lived assets at 406 and 52 stores, respectively. Impairment charges include non-cash charges of $74.9 million and $8.2 million for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively, for the impairment of long-lived assets at 544 and 75 stores, respectively. These amounts include the write-down of long-lived assets at stores that were assessed for impairment because of management's intention to relocate or close the store or because of changes in circumstances that indicate the carrying value of an asset may not be recoverable. During the thirteen week period ended November 29, 2008, we determined that a broader triggering event might have taken place within our store base. Specifically, the broader impairment review was triggered by the increased severity of the economic turmoil and weakening U.S. economy during the quarter, which had a negative impact on the performance relating to a certain number of stores. This broader impairment analysis led to an additional charge for the thirteen week period ended November 29, 2008 of $59.2 million. This amount represents our estimate of impairment for the

31


Table of Contents


quarter and additional amounts could be recorded at year end based upon information available at that time. The charge is primarily due to current and projected operating results at certain of our Brooks Eckerd stores not being sufficient to cover asset values at these stores.

         Goodwill impairment:     We account for goodwill under the guidance set forth in SFAS No. 142, which specifies that goodwill should not be amortized. Our policy is to evaluate goodwill for impairment on an annual basis at the end of our fiscal year or more frequently if events or circumstances occur that would indicate a reduction in the fair value of our company. On November 29, 2008 the carrying value of our net assets was $1,111.2 million and the market capitalization of our outstanding shares, assuming conversion of outstanding preferred shares, was $474.0 million. Accordingly, we performed an interim goodwill impairment test in accordance with SFAS 142. We calculated the estimated fair value of our company as that amount that would be received to sell our company as a whole in an orderly transaction between market participants as of November 29, 2008. We arrived at the estimated fair value by preparing a discounted cash analysis using updated forward looking projections of our estimated future operating results. Based on the results of the discounted cash flow analysis, we concluded that our fair value exceeds our carrying value at November 29, 2008 and that goodwill is not impaired. We also considered as an indicator of market value the market value of our common stock as of November 29, 2008. However, given the extreme volatility in the stock market during the quarter ended November 29, 2008, as well as the impact that the credit crisis and the recession had on the equity markets during that period, and the fact that, after consideration of a control premium, our stock only started to trade below book value during the third quarter, we concluded that it was appropriate to place more reliance on fair value as calculated by our discounted cash flow model in evaluating goodwill impairment as of November 29, 2008. Our continued reliance on our discounted cash flow model may not be appropriate in the future if our market capitalization continues to be less than the carrying value of our net assets. If we determine that we have not passed the step one test of SFAS 142, we believe that the entire recorded amount of goodwill would be impaired under the step two test of SFAS 142.

        The significant assumptions we used in our discounted cash flow analysis include: net income, the discount rate used to present value future cash flows, and capital expenditures. Net income assumptions include sales growth assumptions which are based on our historical trends, including the impact of the converted Brooks Eckerd stores and normal prescription file purchases, but do not include the impact of any new stores or relocated stores. Also included in net income are gross margin and SG&A growth assumptions which are based on the historical relationship of those measures compared to sales and include certain cost cutting initiatives which we began to undertake in the third quarter of 2009. Our discount rate used is a "market participant" weighted average cost of capital ("WAAC") and was 10.5% at November 29, 2008. We assumed a level of capital expenditures of approximately $350,000 to $370,000 per year, which includes the cost of normal prescription file purchases. We performed a sensitivity analysis on our significant assumptions and determined that a reasonable, negative change in its assumptions, as follows, would not impact our conclusion: reduce net income by 10%, increase the WAAC by 100 basis points, or increase capital expenditures by 10%.

         Store and Equipment Lease Exit Charges:     During the thirteen week periods ended November 29, 2008 and December 1, 2007, we recorded charges for 29 and 16 stores, respectively, to be closed or relocated under long-term leases. During the thirty-nine week periods ended November 29, 2008 and December 1, 2007, we recorded charges for 146 and 36 stores, respectively, to be closed or relocated under long-term leases. Charges to close a store, which principally consist of lease termination costs, are recorded at the time the store is closed and all inventory is liquidated, pursuant to the guidance set forth in SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities". We calculate our liability for closed stores on a store-by-store basis. The calculation includes the discounted effect of future minimum lease payments and related ancillary costs, from the date of closure to the end of the remaining lease term, net of estimated cost recoveries that may be achieved through subletting

32


Table of Contents


properties or favorable lease terminations. We evaluate these assumptions each quarter and adjust the liability accordingly.

        As part of our ongoing business activities, we assess stores for potential closure. Decisions to close stores in future periods would result in charges for store lease exit costs and liquidation of inventory, as well as impairment of assets at these stores.

    Interest Expense

        Interest expense was $126.6 million and $363.4 million for the thirteen and thirty-nine week periods ended November 29, 2008, respectively, compared to $130.3 million and $322.3 million for the thirteen and thirty-nine week periods ended December 1, 2007, respectively. The decrease in interest expense for the thirteen week period ended November 29, 2008 was due to a decrease in LIBOR, which decreased interest expense on borrowings under our senior secured credit facility. The increase in interest expense for the thirty-nine week period ended November 29, 2008 was due to increased borrowings to fund the Brooks Eckerd acquisition.

        The weighted average interest rates on our indebtedness for the thirty-nine week periods ended November 29, 2008 and December 1, 2007 were 7.0% and 7.7%, respectively.

    Income Taxes

        We recorded an income tax expense from continuing operations of $29.5 million and an income tax benefit from continuing operations of $52.7 million for the thirteen week periods ended November 29, 2008 and December 1, 2007, respectively, and income tax expense from continuing operations of $39.9 million and income tax benefit from continuing operations of $92.2 million for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively. The expense for income taxes for the thirteen and thirty-nine week period ended November 29, 2008 is primarily attributable to the increase of the valuation allowance on previously recorded federal and state net deferred tax assets. The provision for income taxes for the thirty-nine week period ended December 1, 2007 included a net benefit of $7.9 million for the increase in deferred tax assets as a result of enacted state tax legislation as well as a net benefit of $6.0 million for discrete items related to the recognition of previously unrecognized tax benefits. The discrete items associated with the previously unrecognized tax benefits included tax of $5.2 million and related interest of $2.5 million due to expiration of certain state statutes.

        As a result of the implementation of FIN 48, our tax contingencies decreased $6.6 million, and after the deferred tax impact of $2.2 million, the net effect was accounted for as an increase to retained earnings of $4.4 million. The decrease in unrecognized tax benefits would have decreased income tax expense in prior periods. As of November 29, 2008 the total amount of unrecognized tax benefits that would be recorded as an adjustment to goodwill and not impact the effective tax rate in a future period was $238.0 million. The remaining unrecognized tax benefits would impact the effective tax rate in a future period, although any impact on the effective rate may be mitigated by the valuation allowance that is maintained against our net deferred tax assets. Upon the adoption of SFAS 141(Revised) which applies to our fiscal year 2010, changes in income tax uncertainties recorded in a business combination will also affect income tax expense and will no longer impact goodwill. While it is expected that the amount of unrecognized tax benefits will change in the next twelve months, we do not expect the change to have a significant impact on the results of operations or the financial position of our company.

        We recognize tax liabilities in accordance with FIN 48 and management adjusts these liabilities with changes in judgement as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

33


Table of Contents

        Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109") requires a company to evaluate its deferred tax assets on a regular basis to determine if a valuation allowance against the net deferred tax assets is required. In determining whether a valuation allowance is required, we take into account all available positive and negative evidence with regard to the recognition of a deferred tax asset including our past earnings history, expected future earnings, the character and jurisdiction of such earnings, unsettled circumstances that, if unfavorably resolved, would adversely affect recognition of a deferred tax asset, carryback and carryforward periods, and tax planning strategies that could potentially enhance the likelihood of realization of a deferred tax asset. According to SFAS No. 109, a cumulative loss in recent years is significant negative evidence in considering whether deferred tax assets are realizable. Based on the negative evidence, SFAS No. 109 precludes relying on projections of future taxable income to support the recognition of deferred tax assets. The valuation allowance on federal and state net deferred tax assets was increased during the third quarter of 2009 and the fourth quarter of 2008. The increase for 2009 is related to the impact of the current economic conditions on 2009 results and the filing of the fiscal 2008 income tax returns. If current economic conditions continue, a future increase in the valuation allowance may be required. The ultimate realization of deferred tax assets is dependent upon the existence of sufficient taxable income generated in the carryforward periods.

Liquidity and Capital Resources

    General

        We have four primary sources of liquidity: (i) cash and cash equivalents, (ii) cash provided by operating activities, (iii) the sale of accounts receivable under our receivable securitization agreements and (iv) the revolving credit facility under our senior secured credit facility. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt, to fund capital expenditures and to provide funds for payment of our debt.

    Credit Facility

        Our senior credit facility consists of a $1.75 billion revolving credit facility and three term loans, which are described in subsequent paragraphs. Borrowings under the revolving credit facility currently bear interest at LIBOR plus 1.75%, if we choose to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. The interest rate can fluctuate depending on the amount of revolver availability, as specified in the senior secured credit facility. We are required to pay fees of 0.25% per annum on the daily unused amount of the revolving credit facility. The amounts drawn on the revolving credit facility become due and payable in September 2010.

        Our ability to borrow under the senior secured credit facility is based upon a specified borrowing base consisting of inventory and prescription files. At November 29, 2008, we had $1.146 billion of borrowings outstanding under the revolving credit facility. At November 29, 2008 we also had letters of credit outstanding against the revolving credit facility of $174.3 million, which gave us additional borrowing capacity of $429.7 million.

        In November 2006, we entered into an amendment of our senior secured credit facility and borrowed $145.0 million under a senior secured term loan (the "Tranche 1 Term Loans"). The Tranche 1 Term Loans currently bear interest at LIBOR plus 1.75%, if we choose to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. The interest rate can fluctuate depending on the amount of availability under our revolving credit facility, as specified in the senior secured credit facility. The amounts outstanding under the Tranche 1 Term Loans become due and payable on September 30, 2010, or earlier, if there is a shortfall in our borrowing base under our revolving credit facility.

34


Table of Contents

        On June 4, 2007, we amended our senior secured credit facility to establish a new senior secured term loan in the aggregate principal amount of $1,105.0 million and borrowed the full amount thereunder (the "Tranche 2 Term Loans"). The Tranche 2 Term Loans will mature on June 4, 2014 and currently bear interest at LIBOR plus 1.75%, if we choose to make LIBOR borrowings, or at Citibank's base rate plus 0.75%. We must make mandatory prepayments of the Tranche 2 Term Loans with the proceeds of asset dispositions (subject to certain limitations), with a portion of any excess cash flow generated by us and with the proceeds of certain issuances of equity and debt (subject to certain exceptions). If at any time there is a shortfall in our borrowing base under our revolving credit facility, prepayment of the Tranche 2 Term Loans may also be required.

        On July 9, 2008, we incurred a new senior secured term loan in the aggregate principal amount of $350.0 million (the "Tranche 3 Term Loan") as part of the refinancing of several series of outstanding senior notes. The Tranche 3 Term Loan was issued at a discount of 90% of par. The Tranche 3 Term Loan matures on June 4, 2014 and bears interest at LIBOR (with a minimum LIBOR rate of 3.00%) plus 3.00%, if we choose to make LIBOR borrowings, or at Citibank's base rate (with a minimum base rate of 4.00%) plus 2.00%. We must make mandatory prepayments of the Tranche 3 Term Loan with the proceeds of asset dispositions (subject to certain limitations), with a portion of any excess cash flow and with the proceeds of certain issuances of equity and debt (subject to certain exceptions). If at any time there is a shortfall in our borrowing base under the revolving credit facility, prepayment of the Tranche 3 Term Loan may also be required.

        The senior secured credit facility allows us to have outstanding, at any time, up to $1.5 billion in secured second priority debt and unsecured debt in addition to borrowings under the senior secured credit facility and existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt and unsecured debt shall mature or require scheduled payments of principal prior to three months after September 30, 2014. However, other indentures limit the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence of said debt. The senior secured credit facility allows us to incur an unlimited amount of unsecured debt with a maturity beyond three months after September 30, 2014; however other indentures limit the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence of said debt. The senior secured facility also allows for the repurchase of any debt with a maturity on or before June 4, 2014 and for the voluntary repurchase of debt with a maturity after June 4, 2014 if we maintain availability on the revolving credit facility of at least $100.0 million.

        The senior secured credit facility contains covenants, which place restrictions on the incurrence of debt beyond the restrictions described above, the payment of dividends, mergers and acquisitions and the granting of liens. The senior secured credit facility also requires us to maintain a minimum fixed charge coverage ratio, but only if availability on the revolving credit facility is less than $100.0 million.

        The senior secured credit facility provides for events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables the holder of such debt to accelerate the maturity of such debt.

    Other

        On June 4, 2008, we commenced a tender offer and consent solicitation under which we offered to repurchase all outstanding amounts of our 8.125% senior secured notes due May 2010, our 7.5% senior secured notes due January 2015 and our 9.25% notes due June 2013. On July 8, 2008, the tender offer expired and we repaid $348.9 million of the outstanding balance of our 8.125% notes due May 2010, $199.6 million of our 7.5% notes due January 2015 (and subsequently redeemed the amount that otherwise would have remained outstanding) and $144.0 million of the outstanding balance of our 9.25% senior notes due 2013. As a result of the tender offer and consent solicitation, the indentures

35


Table of Contents

governing these notes were amended to eliminate or modify substantially all restrictive covenants, certain events of default and other provisions contained in the indentures (other than, among other covenants, the covenants to pay interest and premium, if any, on, and principal of, the notes when due), release the subsidiary guarantees and release all the collateral securing the obligations of the subsidiary guarantors under the 8.125% notes and the 7.5% notes. The transaction was done because these notes had restrictions on secured debt that prohibited us from fully drawing on our revolving credit facility under certain circumstances.

        This transaction was financed via the issuance of the Tranche 3 Term Loans and the issuance of a $470.0 million 10.375% senior secured notes due July 2016. The 10.375% senior secured notes due 2016 were issued pursuant to an indenture, dated as of July 9, 2008, among Rite Aid, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee and are unsecured, unsubordinated obligations of Rite Aid and rank equally in right of payment with all of Rite Aid's other unsecured, unsubordinated indebtedness. Rite Aid's obligations under the notes are guaranteed, subject to certain limitations, by all of our subsidiaries that guarantee our obligations under our existing senior secured credit facility, including the Tranche 3 Term Loan, and the 7.5% senior secured notes due 2017. These guarantees are secured, subject to permitted liens, by second priority liens granted by the subsidiary guarantors on all of the assets that secure Rite Aid's obligations under our existing senior secured credit facility. The indenture that governs the 10.375% senior secured notes due 2016 contains covenant provisions that, among other things, include limitations on our ability to pay dividends, make investments or other restricted payments, incur debt, grant liens, sell assets and enter into sale-leaseback transactions. The senior 10.375% secured notes due July 2016 were issued at a discount of 90.588% of par.

        We issued $158.0 million of 8.5% convertible notes due May 2015 in May 2008. These notes are unsecured and unguaranteed and are effectively junior to the secured debt of the Company. The notes are convertible, at the option of the holder, into shares of our common stock at a conversion price of $2.59 per share, subject to adjustments to prevent dilution, at any time. Proceeds from the issuance of these notes were used to fund the redemption of our 6.125% notes due December 2008.

        The indentures that govern our secured and guaranteed unsecured notes contain restrictions on the amount of additional secured and unsecured debt that we can incur. As of November 29, 2008, the amount of additional secured and unsecured debt that could be incurred under these indentures was $812.5 million.

        The aggregate annual principal payments of long-term debt as of November 29, 2008 for the remainder of fiscal 2009 and thereafter are as follows: 2009—$3.9 million; 2010—$16.6 million; 2011—$1,316.9 million; 2012—$14.8 million; 2013—$14.8 million; and $4,759.5 million in 2014 and thereafter. At November 29, 2008 we were in compliance with restrictions and limitations included in the provisions of various loan and credit agreements.

    Sale Leaseback Transactions

        During the thirty-nine week period ended November 29, 2008, we sold a total of 72 owned properties to independent third parties. Net proceeds from these sales were $192.8 million. Concurrent with these sales, we entered into agreements to lease the stores back from the purchasers over minimum lease terms of 20 years. We accounted for 64 of these leases as operating leases and eight are being accounted for under the financing method as these lease agreements contain a clause that allows the buyer to force us to repurchase the property under certain conditions. Gains on these transactions of $3.8 million have been deferred and are being recorded over the related minimum lease terms.

36


Table of Contents

        During the thirty-nine week period ended December 1, 2007, we sold five owned properties to independent third parties. Net proceeds from these sales were approximately $20.8 million. Concurrent with these sales, we entered into agreements to lease these stores back from the purchasers over minimum lease terms of 20 years. We accounted for all of these leases as operating leases. A gain of approximately $1.9 million was deferred and is being recorded over the minimum lease term.

    Off Balance Sheet Obligations

        We maintain receivables securitization agreements with several multi-seller asset-backed commercial paper vehicles ("CPVs"). Under the terms of the securitization agreements, we sell substantially all of our eligible third party pharmaceutical receivables to a bankruptcy remote Special Purpose Entity ("SPE") and retain servicing responsibility. The assets of the SPE are not available to satisfy the creditors of any other person, including any of our affiliates. These agreements provide for us to sell, and for the SPE to purchase these receivables. The SPE then transfers an interest in these receivables to various CPVs. We guarantee certain performance obligations of our affiliates under the securitization agreements, which includes continued servicing of such receivables, but do not guarantee the collectibility of the receivables and obligor creditworthiness. These agreements provide for us to sell, and for the SPE to purchase these receivables. The SPE then transfers an interest in these receivables to various CPVs.

        The securitization agreement expires in September of 2010. Under the terms of the securitization agreement, the CPV's enter into commitments to purchase of no longer than 364 days. The CPV's current commitments to purchase expire on January 15, 2009. The securitization agreement also provides for a backstop credit facility that is supported by the banks under the securitization agreement and that we can access if the CPV's do not renew their commitment to purchase.

        Under the terms of the securitization agreements, the total amount of interest in receivables that can be transferred to the CPVs is $650.0 million. The amount of transferred receivables outstanding at any one time is dependent upon a formula that takes into account such factors as default history, obligor concentrations and potential dilution ("Securitization Formula"). Adjustments to this amount can occur, at the discretion of the CPVs, on a weekly basis. At November 29, 2008 and March 1, 2008, the total outstanding receivables that have been transferred to CPVs were $545.0 million and $435.0 million, respectively. The following table details receivable transfer activity for the thirteen and thirty-nine week periods ended November 29, 2008 and December 1, 2007:

 
  Thirteen Week
Period Ended
  Thrity-Nine Week
Period Ended
 
 
  November 29,
2008
  December 1,
2007
  November 29,
2008
  December 1,
2007
 
 
  (in thousands)
 

Average amount of outstanding receivables transferred

  $ 512,363   $ 320,879   $ 476,429   $ 332,637  

Total receivable transfers

  $ 1,950,000   $ 1,233,000   $ 5,294,000   $ 3,673,000  

Collections made by the Company as part of the servicing arrangement on behalf of the CPVs

  $ 1,905,000   $ 1,123,000   $ 5,184,000   $ 3,623,000  

        At November 29, 2008 and March 1, 2008, we retained an interest in the eligible third party pharmaceutical receivables not transferred to the CPVs of $449.0 million and $493.8 million, respectively, inclusive of the allowance for uncollectible accounts, which was included in accounts receivable, net, on the consolidated balance sheet.

        On September 16, 2008, the securitization agreement was amended. As a result of the amendment, the CPV's extended their commitment to purchase under the securitization agreement to January 15, 2009. Subsequent to January 15, 2009, should any of the CPV's fail to renew or extend their

37


Table of Contents


commitment under these agreements, we continue to have access to a backstop credit facility, which is backed by the banks under the securitization agreement, and which expires in September 2010, to provide liquidity. If we have to draw on the backstop facility, the rate will be LIBOR plus 5.50%. This rate will be applied to the entire facility commitment of $650.0 million. Amounts available under the backstop facility would be dependent upon a formula that takes into account such factors as default history, obligor concentrations and potential dilution and adjustments to the formula would be at the discretion of the banks.

        We are currently in renewal discussions with the banks in the securitization facility. We expect our availability to borrow under the facility to decrease due to expected changes in obligor concentrations. The cost of an amended facility, or cost of funds under the backstop facility, are expected to be greater than the fees currently in place.

        The amendment to the securitization agreement also modified the program and liquidity fees. The program fee is calculated at commercial borrowing rates (which often approximate LIBOR) plus 1.25%, applied to receivables transferred to the CPV's. The liquidity fee is calculated as 1.50% of the total securitization agreement commitment of $650.0 million. The program and the liquidity fees are recorded as a component of selling, general and administrative expenses. Program and liquidity fees for the thirteen week periods ended November 29, 2008 and December 1, 2007 were $7.6 million and $6.3 million, respectively. Program and liquidity fees for the thirty-nine week periods end November 29, 2008 and December 1, 2007 were $16.9 million and $17.3 million, respectively.

        Proceeds from the collections under the receivables securitization agreements are submitted to an independent trustee on a daily basis. The trustee withholds any cash necessary to (1) fund amounts owed to the CPVs as a result of such collections and, (2) fund the CPVs when the Securitization Formula indicates a lesser amount of outstanding receivables transferred is warranted. The remaining collections are swept to our corporate concentration account. At November 29, 2008 and March 1, 2008, we had $2.7 million and $3.3 million of cash, respectively, that was restricted for the payment of trustee fees.

        As of November 29, 2008, we had no material off balance sheet arrangements, other than the receivables securitization agreements described above and operating leases.

    Net Cash Provided by/Used in Operating, Investing and Financing Activities

        Our operating activities provided $35.1 million and used $230.1 million of cash in the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively. In addition to our loss from operations in the thirty-nine week period ended November 29, 2008, operating cash flow was also impacted by interest payments of $303.3 million and increases in inventory due to seasonal inventory build. These items were offset by advances on our accounts receivable securitization facility. The use in operating cash flow for the thirty-nine period ended December 1, 2007 was caused by a net loss of $126.8 million and an increase in inventory, driven primarily by Brooks Eckerd integration activities. The year-on-year improvement in cash flow from operations is due to better expense control and a reduction in inventory.

        Cash used in investing activities was $292.6 million and $2,775.4 million for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively. Cash used in investing activities for the thirty-nine weeks ended November 29, 2008 was for the purchase of property plant equipment ($401.5 million) and prescription files ($75.5 million). Proceeds from sales leaseback transactions of $161.6 million and dispositions of $22.9 million partially offset these expenditures. Cash used in investing activities for the twenty-six week period ended December 1, 2007 was primarily for the acquisition of Brooks Eckerd and purchase of property, plant and equipment and intangible assets offset by proceeds from sale-leaseback transactions and asset dispositions.

38


Table of Contents

        Cash provided by financing activities was $250.5 million and $3,073.0 million for the thirty-nine week periods ended November 29, 2008 and December 1, 2007, respectively. Cash provided by financing activities for the thirty-nine weeks ended November 29, 2008 was due to borrowings on our revolving credit facility to fund our seasonal inventory build and costs incurred for the refinancing of our secured note indentures. Cash provided by financing activities for the thirty-nine week period ended December 1, 2007 was primarily provided by proceeds from issuance of long-term debt utilized to fund the Brooks Eckerd acquisition, and net proceeds from our revolving credit facility.

    Capital Expenditures

        During the thirty-nine week period ended November 29, 2008, we spent $476.9 million on capital expenditures, consisting of $187.6 million related to new store construction, store relocation and store remodel projects, $82.1 million related to technology enhancements, improvements to distribution centers and other corporate requirements, $131.7 million related to the integration of Brooks Eckerd and $75.5 million related to the purchase of prescription files from independent pharmacists. We plan on making total capital expenditures of approximately $550 million during fiscal 2009, consisting of approximately 40% related to new store construction, store relocation, store remodel and store improvement projects, 25% related to the integration of Brooks Eckerd, 15% related to the purchase of prescription files from independent pharmacies and 20% related to technology enhancements, improvements in distribution centers and other corporate requirements. Management expects that these capital expenditures will be financed primarily with cash flow from operating activities, proceeds from sale-leaseback transactions and use of the revolving credit facility. We plan to open or relocate approximately 85 stores in fiscal 2009, with at least 50% being relocated or expanded stores. These relocations and openings will be focused in our strongest existing markets. We also expect to continue remodeling stores.

    Future Liquidity

        We are highly leveraged. Our high level of indebtedness: (i) limits our ability to obtain additional financing; (ii) limits our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) places us at a competitive disadvantage relative to our competitors with less debt; (iv) renders us more vulnerable to general adverse economic and industry conditions including current conditions in the financial markets; and (v) requires us to dedicate a substantial portion of our cash flow to service our debt, including additional debt incurred for the acquisition of Brooks Eckerd. We expect our efforts to maintain our New York Stock Exchange ("NYSE") listing will be successful. However, if our common stock is not listed on the NYSE or another national exchange, holders of our 8.5% convertible notes due 2015 (the "Convertible Notes") will be entitled to require us to repurchase their Convertible Notes. Our senior secured credit facility and accounts receivable securitization facility provide that the occurrence of this repurchase right constitutes a default under such facilities. To avoid such a scenario, we may seek to refinance or amend the terms of the Convertible Notes. We can give no assurance that we would be able to obtain any required financing, including a refinancing, on favorable terms, if at all, or that we would receive any waivers or consents required under our debt instruments. Based upon our current levels of operations, planned improvements in our operating performance, the approval by our stockholders of the proposed reverse stock split and the opportunities that we believe the acquisition of Brooks Eckerd provides, we believe that cash flow from operations together with available borrowings under the senior secured credit facility, sales of accounts receivable under our securitization agreements and other sources of liquidity will be adequate to meet our requirements for working capital, debt service and capital expenditures for the next twelve months. We will continue to assess our liquidity position and potential sources of supplemental liquidity in light of our operating performance, conditions in the financial markets, status of listing of our stock on the New York Stock Exchange and other relevant circumstances. Should we determine, at any time, that it is necessary to obtain additional short-term liquidity, we will evaluate our alternatives and take

39


Table of Contents

appropriate steps to obtain sufficient additional funds. There can be no assurance that any such supplemental funding, if sought, could be obtained or if obtained, would be on terms acceptable to us.

Recent Accounting Pronouncements

        In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". This standard establishes a standard definition for fair value, establishes a framework under generally accepted accounting principles for measuring fair value and expands disclosure requirements for fair value measurements. This standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. In December 2007, a FASB Staff Position (FSP) was proposed to delay the effective dates of SFAS No. 157 as it relates to all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, or at least annually. We have adopted SFAS No. 157 as of March 2, 2008 as it relates to financial assets and liabilities and there was no impact on the financial statements. We are currently evaluating the impact of SFAS No. 157 on nonfinancial assets and liabilities and expect the adoption to have an impact on fair value calculations used in our testing of goodwill, intangibles, and fixed assets for impairment.

        In December 2007, the FASB issued SFAS No. 141 (Revised) "Business Combinations". SFAS 141 (Revised) establishes principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the assets acquired and liabilities assumed in a business combination and makes several changes to the method of accounting for business combinations previously set forth in SFAS No. 141. SFAS No. 141 (Revised) will become effective for acquisitions consummated in fiscal years beginning after December 15, 2008.

Critical Accounting Policies and Estimates

        For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to "Management's Discussion and Analysis of Financial Condition—Critical Accounting Policies and Estimates" included in our fiscal 2008 10-K report.

ITEM 3.    Quantitative and Qualitative Disclosures About Market Risk

        Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions. We currently do not have any derivative transactions outstanding.

        The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of November 29, 2008.

 
  2009   2010   2011   2012   2013   Thereafter   Total   Fair Value at
November 29,
2008
 
 
  (dollars in thousands)
 

Long-term debt, Including current portion

                                                 

Fixed rate

  $ 235   $ 2,038   $ 11,305   $ 215   $ 214   $ 3,404,875   $ 3,418,882   $ 1,246,866  

Average Interest Rate

    7.74 %   4.72 %   8.11 %   7.00 %   7.00 %   8.90 %   8.90 %      

Variable Rate

  $ 3,638   $ 14,550   $ 1,305,550   $ 14,550   $ 14,550   $ 1,354,609   $ 2,707,447   $ 1,829,160  

Average Interest Rate

    5.25 %   5.25 %   4.17 %   5.25 %   5.25 %   5.38 %   4.79 %      

40


Table of Contents

        As of November 29, 2008, 44% of our total debt is exposed to fluctuations in variable interest rates. Proceeds from our sales of accounts receivable under our securitization agreements fluctuate depending on outstanding commercial paper rates, which approximate LIBOR.

        Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations will be materially adversely affected. We cannot assure you that any such borrowing or equity financing could be successfully completed.

ITEM 4.    Controls and Procedures

    (a)
    Disclosure Controls and Procedures

        Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

    (b)
    Changes in Internal Control over Financial Reporting

        There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

41


Table of Contents


PART II. OTHER INFORMATION

ITEM 1.    Legal Proceedings

        We have been contacted by the U.S. Department of Justice, representing the Drug Enforcement Administration concerning certain alleged civil violations of the recordkeeping and reporting requirements of the Controlled Substances Act. We are in continuing discussions with the government on resolving this matter. We have reached an agreement to settle this matter for $5.0 million, which has been reserved against this potential liability. We also agreed, among other things, to maintain an existing compliance program designed to detect and prevent the diversion of controlled substances as required under the Controlled Substances Act.

ITEM 1A.    Risk Factors

        In addition to the other information set forth in this quarterly report, you should carefully consider the risk factors discussed below and disclosed in our Fiscal 2008 10-K and in our 10-Q for the twenty-six week period ended August 30, 2008.

         If we do not meet the New York Stock Exchange continued listing requirements, our common stock may be delisted. In the event that we are not able to regain compliance, we may be required to repurchase or refinance our 8.5% convertible notes due 2015.

        As previously announced, on December 2, 2008, our stockholders approved a reverse split of our common stock at a ratio of 1-for-10, 1-for-15 or 1-for-20. Currently, these ratios would increase the price of our common stock to between $3.50 and $7.00 (based on a closing price of $0.35 on January 5, 2009), which is intended to enable us to comply with the New York Stock Exchange ("NYSE") minimum share price listing rule. The terms of the stockholder approval provide our Board of Directors with the flexibility to determine the split ratio and the effective date of the split based upon its evaluation as to the timing and particular split that will be most advantageous to us and our stockholders. Subject to NYSE rules, we have until April 16, 2009 to regain compliance with the minimum share price rule which requires that the average closing price of our common stock be at least $1.00 for 30 consecutive trading days as of April 16, 2009 and the closing price of our common stock be at least $1.00 on such date. Until such time, our common stock continues to be listed on the NYSE and trades as usual. Moreover, we are in compliance with all other NYSE listing rules and have actively been taking steps to maintain our listing, including the implementation of the reverse stock split. However, there can be no assurance that we will regain or maintain compliance with the NYSE continued listing requirements. If our common stock were delisted, it could: (i) reduce the liquidity and market price of our common stock; (ii) negatively impact our ability to raise equity financing and access the public capital markets; and (iii) materially adversely impact our results of operations and financial condition.

        We expect our efforts to maintain our NYSE listing will be successful. However, if our common stock is not listed on the NYSE or another national exchange, holders of our 8.5% convertible notes due 2015 (the "Convertible Notes") will be entitled to require us to repurchase their Convertible Notes. Our senior secured credit facility and accounts receivable securitization facility provide that the occurrence of this repurchase right constitutes a default under such facilities. To avoid such a scenario, we may seek to refinance or amend the terms of the Convertible Notes. We can give no assurance that we would be able to obtain any required financing, including a refinancing, on favorable terms, if at all, or that we would receive any waivers or consents required under our debt instruments.

ITEM 2.    Unregistered Sales of Equity Securities and Use of Proceeds

        Not applicable.

42


Table of Contents


ITEM 3.    Defaults Upon Senior Securities

        Not applicable.

ITEM 4.    Submission of Matters to a Vote of Security Holders

        No matters were submitted to a vote of the security holders during the thirteen week period ended November 29, 2008.

ITEM 5.    Other Information

        Not applicable.

ITEM 6.    Exhibits

        (a) The following exhibits are filed as part of this report.

Exhibit Numbers
  Description   Incorporation By Reference To
  3.1   Restated Certificate of Incorporation dated December 12, 1996   Exhibit 3(i) to Form 8-K, filed on November 2, 1999

 

3.2

 

Certificate of Amendment to the Restated Certificate of Incorporation dated February 22, 1999

 

Exhibit 3(ii) to Form 8-K, filed on November 2, 1999

 

3.3

 

Certificate of Amendment to the Restated Certificate of Incorporation dated June 27, 2001

 

Exhibit 3.4 to Registration Statement on Form S-1, File No. 333-64950, filed on July 12, 2001

 

3.4

 

Certificate of Amendment to the Restated Certificate of Incorporation dated June 4, 2007

 

Exhibit 4.4 to Registration Statement on Form S-8, filed on October 5, 2007

 

3.5

 

7% Series G Cumulative Convertible Pay-in-Kind Preferred Stock Certificate of Designation dated January 28, 2005

 

Exhibit 3.2 to Form 8-K, filed on February 2, 2005

 

3.6

 

6% Series H Cumulative Convertible Pay-in-Kind Preferred Stock Certificate of Designation dated January 28, 2005

 

Exhibit 3.3 to Form 8-K, filed on February 2, 2005

 

3.7

 

Amended Restated By-laws

 

Exhibit 3.1 to Form 8-K, filed on April 13, 2007

 

3.8

 

Amendment to Sections 1, 3 and 4 of Article 4 of Amended and Restated By-laws

 

Exhibit 3.1 to Form 8-K, filed on December 21, 2000

 

4.1

 

Indenture, dated August 1, 1993 by and between Rite Aid Corporation, as issuer, and Morgan Guaranty Trust Company of New York, as trustee, related to the Company's 7.70% Notes due 2027 and 6.875% Notes due 2013

 

Exhibit 4A to Registration Statement on Form S-3, File No. 333-63794, filed on June 3, 1993

43


Table of Contents

Exhibit Numbers
  Description   Incorporation By Reference To
  4.2   Supplemental Indenture dated as of February 3, 2000, between Rite Aid Corporation, as issuer, and U.S. Bank Trust National Association as successor to Morgan Guaranty Trust Company of New York, to the Indenture dated as of August 1, 1993, relating to the Company's 7.70% Notes due 2027 and 6.875% Notes due 2013   Exhibit 4.1 to Form 8-K filed on February 7, 2000

 

4.3

 

Indenture, dated as of December 21, 1998, between Rite Aid Corporation, as issuer, and Harris Trust and Savings Bank, as trustee, related to the Company's 6.875% Notes due 2028

 

Exhibit 4.1 to Registration Statement on Form S-4, File No. 333-74751, filed on March 19, 1999

 

4.4

 

Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and Harris Trust and Savings Bank, to the Indenture dated December 21, 1998, between Rite Aid Corporation and Harris Trust and Savings Bank, related to the Company's 6.875% Notes due 2028

 

Exhibit 4.4 to Form 8-K filed on February 7, 2000

 

4.5

 

Indenture, dated as of April 22, 2003, between Rite Aid Corporation, as issuer, and BNY Midwest Trust Company, as trustee, related to the Company's 8.125% Senior Secured Notes due 2010

 

Exhibit 4.11 to Form 10-K, filed on May 2, 2003

 

4.6

 

Supplemental Indenture, dated as of June 4, 2007, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A. to the Indenture dated as of April 22, 2003 between Rite Aid Corporation and BNY Midwest Trust Company, related to the Company's 8.125% Senior Secured Notes due 2010

 

Exhibit 4.6 to Form 10-Q, filed on July 12, 2007

 

4.7

 

Second Supplemental Indenture, dated as of June 17, 2008, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A., to the Indenture dated as of April 22, 2003 between Rite Aid Corporation and BNY Midwest Trust Company, related to the Company's 8.125% Senior Secured Notes due 2010

 

Exhibit 4.7 to Form 10-Q, filed on July 10, 2008

 

4.8

 

Indenture, dated as of May 20, 2003, between Rite Aid Corporation, as issuer, and BNY Midwest Trust Company, as trustee, related to the Company's 9.25% Senior Notes due 2013

 

Exhibit 4.12 to Form 10-Q, filed on July 3, 2003

44


Table of Contents

Exhibit Numbers
  Description   Incorporation By Reference To
  4.9   Supplemental Indenture, dated as of June 4, 2007, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A. to the Indenture dated as of May 20, 2003 between Rite Aid Corporation and BNY Midwest Trust Company, related to the Company's 9.25% Senior Secured Notes due 2013   Exhibit 4.8 to Form 10-Q, filed on July 12, 2007

 

4.10

 

Second Supplemental Indenture, dated as of June 17, 2008, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A., as successor trustee, to the Indenture dated as of May 20, 2003 between Rite Aid Corporation and BNY Midwest Trust Company, related to the Company's 9.25% Senior Secured Notes due 2013

 

Exhibit 4.10 to Form 10-Q, filed on July 10, 2008

 

4.11

 

Indenture, dated as of February 15, 2007, between Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Trust Company, N.A., as trustee, related to the Company's 7.5% Senior Secured Notes due 2017

 

Exhibit 99.1 to Form 8-K, filed on February 26, 2007

 

4.12

 

Supplemental Indenture, dated as of June 4, 2007, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A. to the Indenture dated as of February 21, 2007 between Rite Aid Corporation and The Bank of New York Trust Company, N.A., related to the Company's 7.5% Senior Secured Notes due 2017

 

Exhibit 4.12 to Form 10-Q, filed on July 12, 2007

 

4.13

 

Second Supplemental Indenture, dated as of July 9, 2008, among Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Mellon Trust Company, N. A., as successor trustee, to the Indenture, dated as of February 15, 2007, between Rite Aid Corporation and The Bank of New York Trust Company, N.A., related to the Company's 7.5% Senior Secured Notes due 2017

 

Exhibit 4.7 to Form 10-Q, filed on July 10, 2008

 

4.14

 

Indenture, dated as of February 15, 2007, between Rite Aid Corporation, as issuer, and The Bank of New York Trust Company, N.A., as trustee, related to the Company's 8.625% Senior Notes due 2015

 

Exhibit 99.2 to Form 8-K, filed on February 26, 2007

45


Table of Contents

Exhibit Numbers
  Description   Incorporation By Reference To
  4.15   Supplemental Indenture, dated as of June 4, 2007, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A. to the Indenture dated as of February 21, 2007 between Rite Aid Corporation and The Bank of New York Trust Company, N.A., related to the Company's 8.625% Senior Secured Notes due 2015   Exhibit 4.14 to Form 10-Q, filed on July 12, 2007

 

4.16

 

Second Supplemental Indenture, dated as of July 9, 2008, among Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Mellon Trust Company, N. A., as successor trustee, to the Indenture, dated as of February 15, 2007, between Rite Aid Corporation and The Bank of New York Trust Company, N. A., related to the Company's 8.625% Senior Notes due 2015

 

Exhibit 4.16 to Form 10-Q, filed on July 10, 2008

 

4.17

 

Amended and Restated Indenture, dated as of June 4, 2007 among Rite Aid Corporation (as successor to Rite Aid Escrow Corp.), the subsidiary guarantors named therein and The Bank of New York Trust Company, N.A., as Trustee, related to the Company's 9.375% Senior Notes due 2015

 

Exhibit 4.1 to Form 8-K, filed on June 7, 2007

 

4.18

 

First Supplemental Indenture, dated as of July 9, 2008, among Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Mellon Trust Company, N. A. to the Amended and Restated Indenture, dated as of June 4, 2007, among Rite Aid Corporation (as successor to Rite Aid Escrow Corp.), the subsidiary guarantors named therein and The Bank of New York Trust Company, N.A., related to the Company's 9.375% Senior Notes due 2015

 

Exhibit 4.7 to Form 10-Q, filed on July 10, 2008

 

4.19

 

Amended and Restated Indenture, dated as of June 4, 2007 among Rite Aid Corporation (as successor to Rite Aid Escrow Corp.), the subsidiary guarantors named therein and The Bank of New York Trust Company, N.A., as Trustee, related to the Company's 9.5% Senior Notes due 2017

 

Exhibit 4.2 to Form 8-K, filed on June 7, 2007

46


Table of Contents

Exhibit Numbers
  Description   Incorporation By Reference To
  4.20   First Supplemental Indenture, dated as of July 9, 2008, among Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Mellon Trust Company, N. A., as successor trustee, to the Amended and Restated Indenture, dated as of June 4, 2007, among Rite Aid Corporation (as successor to Rite Aid Escrow Corp.), the subsidiary guarantors named therein and The Bank of New York Trust Company, N.A., related to the Company's 9.5% Senior Notes due 2017   Exhibit 4.20 to Form 10-Q, filed on July 10, 2008

 

4.21

 

Indenture, dated as of May 29, 2008, between Rite Aid Corporation, as issuer, and The Bank of New York Trust Company, N.A., as trustee, related to the Company's Senior Debt Securities

 

Exhibit 4.21 to Form 10-Q, filed on July 10, 2008

 

4.22

 

First Supplemental Indenture, dated as of May 29, 2008, between Rite Aid Corporation, the subsidiaries named therein and The Bank of New York Trust Company, N.A. to the Indenture dated as of May 29, 2008 between Rite Aid Corporation and The Bank of New York Trust Company, N.A., related to the Company's Senior Debt Securities

 

Exhibit 4.22 to Form 10-Q, filed on July 10, 2008

 

4.23

 

Indenture, dated as of July 9, 2008, between Rite Aid Corporation, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee, related to the Company's 10.375% Senior Secured Notes due 2016

 

Exhibit 4.7 to Form 10-Q, filed on July 10, 2008

 

4.24

 

Registration Rights Agreement, dated August 23, 2006, by and between Rite Aid Corporation and The Jean Coutu Group (PJC) Inc.

 

Exhibit 10.2 to Form 8-K, filed on August 24, 2006

 

4.25

 

Amended and Restated Stockholder Agreement, dated August 23, 2006, amended and restated as of June 4, 2007, by and between Rite Aid Corporation, The Jean Coutu Group (PJC) Inc., Jean Coutu, Marcelle Coutu, Francois J. Coutu, Michel Coutu, Louis Coutu, Sylvie Coutu and Marie-Josee Coutu

 

Exhibit 2.2 to Form 10-Q, filed on July 12, 2007

 

10.1

 

Second Amendment to Supply Agreement by and between Rite Aid Corporation and McKesson Corporation, dated as of November 7, 2008*

 

Filed herewith

47


Table of Contents

Exhibit Numbers
  Description   Incorporation By Reference To
  10.2   Amendment No. 1 to Employment Agreement by and between Rite Aid Corporation and Robert B. Sari, dated as of December 18, 2008   Filed herewith

 

10.3

 

Amendment No. 1 to Employment Agreement by and between Rite Aid Corporation and Brian Fiala, dated as of December 18, 2008

 

Filed herewith

 

10.4

 

Amendment No. 1 to Employment Agreement by and between Rite Aid Corporation and Douglas E. Donley, dated as of December 18, 2008

 

Filed herewith

 

10.5

 

Amendment No. 3 to Employment Agreement by and between Rite Aid Corporation and Robert G. Miller, dated as of December 23, 2008

 

Filed herewith

 

10.6

 

Amendment No. 3 to Employment Agreement by and between Rite Aid Corporation and Mary F. Sammons, dated as of December 30, 2008

 

Filed herewith

 

10.7

 

Employment Agreement by and between Rite Aid Corporation and Ken Martindale, dated as of December 3, 2008

 

Filed herewith

 

11

 

Statement regarding computation of earnings per share. (See Note 4 to the condensed consolidated financial statements)

 

Filed herewith

 

31.1

 

Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended

 

Filed herewith

 

31.2

 

Certification of CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended

 

Filed herewith

 

32

 

Certification of CEO and CFO pursuant to 18 United States Code, Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002

 

Filed herewith

*
Confidential portions of this Exhibit were redacted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

48


Table of Contents


SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 7, 2009   RITE AID CORPORATION

 

 

By:

 

/s/ ROBERT B. SARI

Robert B. Sari
Executive Vice President and General Counsel

Date: January 7, 2009

 

By:

 

/s/ FRANK G. VITRANO

Frank G. Vitrano
Chief Financial Officer and
Chief Administrative Officer

49




Exhibit 10.1

 

Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omissions have been indicated by “[***Redacted***]” , and the omitted text has been filed separately with the Securities and Exchange Commission.

 

SECOND AMENDMENT TO SUPPLY AGREEMENT

 

This Second Amendment to the Supply Agreement (the “Second Amendment”) is entered into the 7th day of November, 2008, by and between Rite Aid Corporation (“Rite Aid”) and McKesson Corporation (“McKesson”).

 

INTRODUCTION

 

Pursuant to the terms of the Supply Agreement dated December 22, 2003 (the “Rite Aid Agreement”) as amended by the First Amendment to the Supply Agreement dated December 8, 2007 (the “First Amendment”) (collectively referred to herein as the “Agreement”), McKesson and Rite Aid entered into an agreement to establish a program for McKesson’s supply of pharmaceutical and OTC products to Rite Aid.

 

AGREEMENT

 

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, McKesson and Rite Aid hereby agree as follows:

 

1.                                        Effective as of the first day of the first full month following the Second Amendment Effective Date (as hereinafter defined), Section 3.1 of the Agreement is hereby deleted and replaced with the following:

 

3.1                                Warehouse.  The Cost of Goods for Warehouse purchases of Products, other than Branded Rx Warehouse Repackaged Products and OneStop Generics, shall be the [***Redacted***] .

 

2.                                        Effective as of the first day of the first full month following the Second Amendment Effective Date (as hereinafter defined), the following is hereby added as Section 3.9(a) of the Agreement:

 

3.9                                Additional Rebates.

 

(a)                                   Buy Profit Rebate.   McKesson will issue to Rite Aid a rebate, in the form of a credit, in an amount equal to [***Redacted***] of the Cost of Goods for Branded Rx Warehouse purchases (net of Branded Rx Warehouse returns as provided in Section 8.1 and excluding Branded Rx Warehouse Repackaged Merchandise) (the “Buy Profit Rebate”). The Buy Profit Rebate shall be paid each week on Tuesday for purchases made from Saturday to Friday of the previous week, unless Tuesday is a McKesson recognized holiday, in which case the rebate shall be paid on the next business day.  An illustration of the Buy Profit Rebate calculation is set forth below:

 

Total monthly
Branded Rx
Warehouse
Purchases

 

(-)
Branded Rx
Warehouse
Returns
(Includes
returns to
vendors)

 

(-)
Branded Rx
Warehouse
Repackaged
purchases

 

(X)
Buy Profit
Rebate of
[***Redacted***]

 

(=)
Buy Profit Rebate

 

$

100,000,000

 

$

100,000

 

$

8,000,000

 

[***Redacted***]

 

[***Redacted***]

 

 

1



 

3.                                        Effective as of the first day of the first full month following the Second Amendment Effective Date (as hereinafter defined), the fourth paragraph of Section 3.9(b) of the Agreement is hereby deleted and replaced with the following:

 

(b)                                  Additional Rebates on Branded Rx Warehouse Purchases.   For the Contract Year which ended on November 30, 2007 (“Contract Year Ended 11/30/07”), the Annual Market Basket rebate shall be paid on [***Redacted***] of Branded Rx Products purchases (net of Branded Rx Warehouse returns as provided in Section 8.1 and rebates or other incentives hereunder and excluding Branded Rx Warehouse Repackaged purchases) by the three original Rite Aid warehouses designated as Perryman, Tuscaloosa and Woodland.

 

For subsequent Contract Years following the Contract Year Ended 11/30/07, all purchases from Rite Aid warehouses shall be included in the calculation of the Market Basket Rebate.  The purchases eligible for the Market Basket Rebate shall be reduced by the amount of the previous twelve (12) months of the Buy Profit Rebate.

 

For the subsequent Contract Years following the Contract Year Ended 11/30/07, the Annual Market Basket Index Adjustment chart found in Section 3.9(b) shall be replaced by the chart below.

 

Annual Market Basket Index Adjustment

 

Rite Aid’s Achieved Annual Market

 

 

 

Basket Price Increase Rate

 

Rebate on Annual Branded

 

From

 

To

 

Rx Warehouse purchases

 

 

 

 

 

 

 

[***Redacted***]

 

 

 

[***Redacted***]

 

 

[***Redacted***]

 

In this example, McKesson would pay Rite Aid a [***Redacted***] on purchases of Branded Rx Warehouse purchases (less the Buy Profit Rebate) during this Contract Year no later than [***Redacted***] .

 

($1,000,000.00 - [***Redacted***]) X [***Redacted***] = [***Redacted***]

 

Dollar volume – Buy Profit Rebate X applicable Market Basket Rebate %

 

4.                                        In consideration of various purchase commitments set forth in this Agreement, Rite Aid shall be eligible to earn a one-time rebate equal to [***Redacted***] of the dollar volume of DSD and Warehouse purchases (less all returns) by Rite Aid, during the first thirty (30) days after the Second Amendment Effective Date (as hereinafter defined) (“Purchase Volume Rebate”).  Notwithstanding anything in the foregoing, in no event shall such Purchase Volume Rebate exceed [***Redacted***] .  Such Purchase Volume Rebate shall be paid to Rite Aid no later than fifteen (15) days following the close of the above-referenced 30 day period.

 

5.                                        This Second Amendment shall become effective on the first date on which both Rite Aid and McKesson shall have executed said Second Amendment (“Second Amendment Effective Date”).

 

6.                                        Except as amended above, the Agreement remains unchanged and in full force and effect.  Capitalized terms used in this Second Amendment and not otherwise defined herein shall have the meaning given to them in the Agreement.

 

2



 

7.                                        This Second Amendment may be executed in counterparts, each of which shall constitute an original.

 

8.                                        This Second Amendment, together with the Rite Aid Agreement and the First Amendment , embodies the entire agreement between the parties with regard to the subject matter hereof and supersedes all prior agreements understanding and representations with the exception of any promissory note, security agreement or other credit or financial related document(s) executed by or between Rite Aid and McKesson.

 

IN WITNESS WHEREOF the parties have caused this Second Amendment to be duly executed as of the date and year written below and the persons signing warrant that they are duly authorized to sign for and on behalf of the respective parties.  This Second Amendment shall be deemed accepted by McKesson only upon execution by a duly authorized representative of McKesson.

 

RITE AID CORPORATION

 

McKESSON CORPORATION

 

 

 

By:

/s/ Robert B. Sari

 

By:

/s/ Paul C. Julian

 

 

 

Name:

Robert B. Sari

 

Name:

Paul C. Julian

 

 

 

Title:

Executive Vice President, General Counsel

 

Title:

Executive Vice President, Group President

 

General Counsel and Secretary

 

 

 

 

 

Date:

November 7, 2008

 

Date:

November 7, 2008

 

3




Exhibit 10.2

 

AMENDMENT NO. 1 TO

EMPLOYMENT AGREEMENT

 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, by and between Rite Aid Corporation, a Delaware Corporation (the “Company”) and Robert B. Sari (“Executive”) is entered into as of the 18th day of December, 2008.

 

WHEREAS, Executive and the Company previously entered into that certain employment agreement, dated as of February 28, 2001 (the “Employment Agreement” or “Agreement”); and

 

WHEREAS, the Company and the Executive now desire to amend the Employment Agreement to: (i) reflect the change in Executive’s duties, compensation and other benefits in connection with his transition from his current position as Executive Vice President, General Counsel; and (ii) to ensure compliance with Internal Revenue Code Section 409A and the final regulations promulgated thereunder;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

 

1.             New Section 14 .  Effective as of January 1, 2005, the following new Section 14 shall be inserted into the Employment Agreement.  In the event of an inconsistency between this new Section 14 and the remaining provisions of the Employment Agreement, Section 14 shall govern.

 

“14.         COMPLIANCE WITH CODE SECTION 409A   Notwithstanding anything in this Employment Agreement to the contrary, effective as of January 1, 2005, the following provisions shall govern:  The provisions listed below are intended to be compliant with Internal Revenue Code (“Code”) Section 409A and the final regulations promulgated thereunder (‘409A’) and shall be construed to be so compliant.

 

(a)                                   Good Reason: Any termination for ‘Good Reason’ shall comply with the safe harbor definition of ‘good reason’ in 409A, including the condition giving rise to such termination and the notice and cure period provided for in 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

(I)                                     The final paragraph of Section 5.4 of the Agreement shall be modified to read as follows:

 



 

‘provided, however that the Executive has provided written notice (which shall set forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provisions of this Agreement on which Executive relies) to the Company of the existence of any condition described in any one of subparagraphs a, b, or c within 30 days of the initial existence of such condition, and the Company has not cured the condition within 30 days of the receipt of such notice.  Any termination of employment by the Executive for Good Reason pursuant to Section 5.3 must occur no later than the date that is the second anniversary of the initial existence of the condition giving rise to the termination right.’

 

(b)                                  Payment of Benefits : To the extent necessary to avoid adverse tax consequences, and except as described below, any payment to which the Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon the Executive’s termination; (b) at a time when the Executive is a “specified employee” as defined by 409A shall not be made until the earliest of:

 

(1)                                   the expiration of the six month period (the “Deferral Period”) measured from the date of the Executive’s ‘separation from service’ under 409A; or

(2)                                   the date of the Executive’s death.

 

Upon the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to the Executive or, if applicable, his beneficiary.  This section shall not apply to any payment which constitutes “separation pay” as described in Internal Revenue Regulations Section 409A-1(b)(9) (in general, payments (i) that are made on an involuntary separation from service which (ii) do not exceed the lesser of two times (x) the Executive’s annualized compensation for the taxable year preceding the year in which the separation from service occurs or (y) the Code Section 401(a)(17) limit on compensation for the year in which separation from service occurs and (iii) are paid in total by the end of the second calendar year following the calendar year in which the separation from service occurs.)

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 



 

‘The Company shall pay to the Executive the Accrued Benefits, within ten (10) days after the Date of Termination.  Notwithstanding the foregoing, if the Executive is a ‘specified employee’, as defined in 409A, the Company shall pay to the Executive the Accrued Benefits on the six (6) month anniversary of the Date of Termination.

 

To the extent permissible by law, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment’

 

(c )                                Reimbursements :  To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:

 

(1)           The right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit;

(2)           The amount of expenses or in kind benefits available or paid in one year shall not affect the amount available or paid in any subsequent year; and

(3)           Such payments shall be made on or before the last day of the Executive’s taxable year in which the expense occurred.

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 4.2 of the Agreement shall be modified to insert the following sentence at the end thereof:

 

‘The provisions of Section 14(c)  shall apply to all reimbursements made under this Section 4.2.’

 

(d)                                  Medical Benefits :  The provision of medical benefits after separation from service shall be done in a manner to, to the extent possible, exempt such benefits from the application of 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5.3(a) and 5.5(a) of the Agreement shall be modified by adding the following to the end thereof:

 

‘For any period during which the Executive would be entitled to continuation coverage through the application of

 



 

Internal Revenue Code Section 4980B (‘COBRA’), this coverage shall be provided at the expense of the Company.  For any period after the expiration of the period required by COBRA, but prior to the end of the month in which the second anniversary of the Date of Termination occurs, this coverage will be provided at the expense of the Executive (or his beneficiaries or estate).  Executive (or his beneficiaries or estate) shall remit payment by check to the Company in the amount of the then current amount used to calculate premiums for participants entitled to receive continuation coverage under COBRA.  The Company shall, on the last day of each month, provide the Executive (or his beneficiaries or estate) with a payment sufficient to place the Executive (or his beneficiaries or estate) in the same economic position had such individuals or entity not been required to pay the premium described in the preceding sentence.’”

 

2.   Term.    Executive shall continue to perform the services and fulfill the duties, position and responsibilities under his Employment Agreement or as assigned to him by the Chief Executive Officer until July 1, 2009 or such earlier separation date that Executive designates on no less than 30 days’ advance written notice to Company (the “Separation Date”). On the Separation Date, Executive’s employment with the Company shall terminate.

 

3.  Compensation and Benefits . In consideration for the continued services to be provided by the Executive, the Company shall provide to Executive the following compensation and benefits: (i) commencing January 1, 2009 through the Separation Date, Executive will work on a full time basis from the Company’s headquarters three weeks per month. One week per month Executive may perform his duties from Portland, Oregon, if he so desires; (ii) commencing January 1, 2009 through the Separation Date, Executive’s salary will be adjusted to a rate of $550,000.00 per year, paid on a bi weekly basis. Executive will not be eligible for a salary increase effective March 2009; (iii) Fiscal Year 2009 bonus (if earned) will be paid to the Executive consistent with the Rite Aid Corporate Bonus Plan document. Executive will not be eligible for a fiscal 2010 bonus; (iv) Executive will be eligible for a retention bonus in the amount of $330,000.00 (60% incentive target), to be paid as follows; (a) $165,000.00 to be paid by March 1, 2009, (b) $165,000.00 to be paid by July 1, 2009. If Executive voluntarily resigns his position prior to these payment dates, he will not be eligible for the retention; (v) any earned vacation will be cashed out following separation as per Company policy.

 



 

4.             Employment Agreement to Remain in Effect .           Except as modified by this Amendment No. 1, the Employment Agreement shall remain in full force and effect in accordance with its terms.  In the event of a conflict between the provisions of this Amendment No. 1 and the Employment Agreement, this Amendment No. 1 shall be controlling.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

By:

/s/ Robert B. Sari

 

Its:

Executive Vice President, General Counsel

 

 

 

 

 

ROBERT B. SARI

 

 

 

/s/ Robert B. Sari

 




Exhibit 10.3

 

AMENDMENT NO. 1 TO

EMPLOYMENT AGREEMENT

 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, by and between Rite Aid Corporation, a Delaware Corporation (the “Company”) and Brian Fiala (“Executive”) is entered into as of the 18th day of December, 2008.  The provisions of this Amendment shall be effective as of June 26, 2007 (the “Effective Date”).

 

WHEREAS, Executive and the Company previously entered into that certain employment agreement, dated as of June 26, 2007 (the “Employment Agreement” or “Agreement”); and

 

WHEREAS, the Company and the Executive now desire to amend the Employment Agreement to ensure compliance with Internal Revenue Code Section 409A and the final regulations promulgated thereunder;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

 

1.             New Section 14 .  Effective as of the Effective Date, the following new Section 14 shall be inserted into the Employment Agreement.  In the event of an inconsistency between this new Section 14 and the remaining provisions of the Employment Agreement, Section 14 shall govern.

 

“14.         COMPLIANCE WITH CODE SECTION 409A   Notwithstanding anything in this Employment Agreement to the contrary, effective as of Effective Date, the following provisions shall govern:  The provisions listed below are intended to be compliant with Internal Revenue Code (“Code”) Section 409A and the final regulations promulgated thereunder (‘409A’) and shall be construed to be so compliant.

 

(a)                                   Good Reason: Any termination for ‘Good Reason’ shall comply with the safe harbor definition of ‘good reason’ in 409A, including the condition giving rise to such termination and the notice and cure period provided for in 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of the Effective Date:

 

(i)                                      The final paragraph of Section 5.4 of the Agreement shall be modified to read as follows:

 

‘provided, however that the Executive has provided written notice (which shall set forth in reasonable detail the

 



 

specific conduct of the Company that constitutes Good Reason and the specific provisions of this Agreement on which Executive relies) to the Company of the existence of any condition described in any one of subparagraphs a, b, or c within 30 days of the initial existence of such condition, and the Company has not cured the condition within 30 days of the receipt of such notice.  Any termination of employment by the Executive for Good Reason pursuant to Section 5.3 must occur no later than the date that is the second anniversary of the initial existence of the condition giving rise to the termination right.’

 

(b)                                  Payment of Benefits : To the extent necessary to avoid adverse tax consequences, and except as described below, any payment to which the Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon the Executive’s termination; (b) at a time when the Executive is a “specified employee” as defined by 409A shall not be made until the earliest of:

 

(1)                                   the expiration of the six month period (the “Deferral Period”) measured from the date of the Executive’s ‘separation from service’ under 409A; or

(2)                                   the date of the Executive’s death.

 

Upon the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to the Executive or, if applicable, his beneficiary.  This section shall not apply to any payment which constitutes “separation pay” as described in Internal Revenue Regulations Section 409A-1(b)(9) (in general, payments (i) that are made on an involuntary separation from service which (ii) do not exceed the lesser of two times (x) the Executive’s annualized compensation for the taxable year preceding the year in which the separation from service occurs or (y) the Code Section 401(a)(17) limit on compensation for the year in which separation from service occurs and (iii) are paid in total by the end of the second calendar year following the calendar year in which the separation from service occurs.)

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of the Effective Date:

 

‘The Company shall pay to the Executive the Accrued Benefits within ten (10) days after the Date of Termination.

 



 

Notwithstanding the foregoing, if the Executive is a ‘specified employee’, as defined in 409A, the Company shall pay to the Executive the Accrued Benefits on the six (6) month anniversary of the Date of Termination.

 

To the extent permissible by law, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment’

 

(c)                                   Reimbursements :  To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:

 

(1)           The right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit;

(2)           The amount of expenses or in kind benefits available or paid in one year shall not affect the amount available or paid in any subsequent year; and

(3)           Such payments shall be made on or before the last day of the Executive’s taxable year in which the expense occurred.

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of the Effective Date:

 

Section 4.2 of the Agreement shall be modified to insert the following sentence at the end thereof:

 

‘The provisions of Section 14(c) shall apply to all reimbursements made under this Section 4.2.’

 

(d)                                  Medical Benefits :  The provision of medical benefits after separation from service shall be done in a manner to, to the extent possible, exempt such benefits from the application of 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of the Effective Date:

 

Section 5.3(a)  of the Agreement shall be modified by adding the following to the end thereof:

 

‘For any period during which the Executive would be entitled to continuation coverage through the application of Internal Revenue Code Section 4980B (‘COBRA’), this coverage shall be provided at the expense of the Company.  For any period after the expiration of the period required by COBRA, but prior to the end of the month in which the second anniversary of the Date of Termination occurs, this

 



 

coverage will be provided at the expense of the Executive (or his beneficiaries or estate).  Executive (or his beneficiaries or estate) shall remit payment by check to the Company in the amount of the then current amount used to calculate premiums for participants entitled to receive continuation coverage under COBRA.  The Company shall, on the last day of each month, provide the Executive (or his beneficiaries or estate) with a payment sufficient to place the Executive (or his beneficiaries or estate) in the same economic position had such individuals or entity not been required to pay the premium described in the preceding sentence.’”

 

2.             Employment Agreement to Remain in Effect .            Except as modified by this Amendment No. 1, the Employment Agreement shall remain in full force and effect in accordance with its terms.  In the event of a conflict between the provisions of this Amendment No. 1 and the Employment Agreement, this Amendment No. 1 shall be controlling.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

By:

/s/ Robert B. Sari

 

Its:

Executive Vice President, General Counsel

 

 

 

 

 

BRIAN FIALA

 

 

 

/s/ Brian Fiala

 




Exhibit 10.4

 

AMENDMENT NO. 1 TO

EMPLOYMENT AGREEMENT

 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, by and between Rite Aid Corporation, a Delaware Corporation (the “Company”) and Douglas E Donley (“Executive”) is entered into as of the 18th day of December, 2008.  The provisions of this Amendment shall be effective as of January 1, 2005 (the “Effective Date”).

 

WHEREAS, Executive and the Company previously entered into that certain employment agreement, dated as of August 1, 2000 (the “Employment Agreement” or “Agreement”); and

 

WHEREAS, the Company and the Executive now desire to amend the Employment Agreement to ensure compliance with Internal Revenue Code Section 409A and the final regulations promulgated thereunder;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

 

1.              New Section 14 .  Effective as of the Effective Date, the following new Section 14 shall be inserted into the Employment Agreement.  In the event of an inconsistency between this new Section 14 and the remaining provisions of the Employment Agreement, Section 14 shall govern.

 

“14.          COMPLIANCE WITH CODE SECTION 409A   Notwithstanding anything in this Employment Agreement to the contrary, effective as of January 1, 2005, the following provisions shall govern:  The provisions listed below are intended to be compliant with Internal Revenue Code (“Code”) Section 409A and the final regulations promulgated thereunder (‘409A’) and shall be construed to be so compliant.

 

(a)            Good Reason: Any termination for ‘Good Reason’ shall comply with the safe harbor definition of ‘good reason’ in 409A, including the condition giving rise to such termination and the notice and cure period provided for in 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

(i)             The final paragraph of Section 5.4 of the Agreement shall be modified to read as follows:

 



 

‘provided, however that the Executive has provided written notice (which shall set forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provisions of this Agreement on which Executive relies) to the Company of the existence of any condition described in any one of subparagraphs a, b, or c within 30 days of the initial existence of such condition, and the Company has not cured the condition within 30 days of the receipt of such notice.  Any termination of employment by the Executive for Good Reason pursuant to Section 5.3 must occur no later than the date that is the second anniversary of the initial existence of the condition giving rise to the termination right.’

 

(b)            Payment of Benefits : To the extent necessary to avoid adverse tax consequences, and except as described below, any payment to which the Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon the Executive’s termination; (b) at a time when the Executive is a “specified employee” as defined by 409A shall not be made until the earliest of:

 

(1)            the expiration of the six month period (the “Deferral Period”) measured from the date of the Executive’s ‘separation from service’ under 409A; or

(2)            the date of the Executive’s death.

 

Upon the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to the Executive or, if applicable, his beneficiary.  This section shall not apply to any payment which constitutes “separation pay” as described in Internal Revenue Regulations Section 409A-1(b)(9) (in general, payments (i) that are made on an involuntary separation from service which (ii) do not exceed the lesser of two times (x) the Executive’s annualized compensation for the taxable year preceding the year in which the separation from service occurs or (y) the Code Section 401(a)(17) limit on compensation for the year in which separation from service occurs and (iii) are paid in total by the end of the second calendar year following the calendar year in which the separation from service occurs.)

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 



 

‘The Company shall pay to the Executive the Accrued Benefits, within ten (10) days after the Date of Termination.  Notwithstanding the foregoing, if the Executive is a ‘specified employee’, as defined in 409A, the Company shall pay to the Executive the Accrued Benefits on the six (6) month anniversary of the Date of Termination.

 

To the extent permissible by law, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment’

 

(c)            Reimbursements :  To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:

 

(1)            The right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit;

(2)            The amount of expenses or in kind benefits available or paid in one year shall not affect the amount available or paid in any subsequent year; and

(3)            Such payments shall be made on or before the last day of the Executive’s taxable year in which the expense occurred.

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 4.2 of the Agreement shall be modified to insert the following sentence at the end thereof:

 

‘The provisions of Section 14(c) shall apply to all reimbursements made under this Section 4.2.’

 

(d)            Medical Benefits :  The provision of medical benefits after separation from service shall be done in a manner to, to the extent possible, exempt such benefits from the application of 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5.3(a) and 5.5(a) of the Agreement shall be modified by adding the following to the end thereof:

 

‘For any period during which the Executive would be entitled to continuation coverage through the application of Internal Revenue Code Section 4980B (‘COBRA’), this coverage shall be provided at the expense of the Company. 

 



 

For any period after the expiration of the period required by COBRA, but prior to the end of the month in which the second anniversary of the Date of Termination occurs, this coverage will be provided at the expense of the Executive (or his beneficiaries or estate).  Executive (or his beneficiaries or estate) shall remit payment by check to the Company in the amount of the then current amount used to calculate premiums for participants entitled to receive continuation coverage under COBRA.  The Company shall, on the last day of each month, provide the Executive (or his beneficiaries or estate) with a payment sufficient to place the Executive (or his beneficiaries or estate) in the same economic position had such individuals or entity not been required to pay the premium described in the preceding sentence.’”

 

2.              Employment Agreement to Remain in Effect .   Except as modified by this Amendment No. 1, the Employment Agreement shall remain in full force and effect in accordance with its terms.  In the event of a conflict between the provisions of this Amendment No. 1 and the Employment Agreement, this Amendment No. 1 shall be controlling.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

 

 

 

By:

/s/ Robert B. Sari

 

Its:

Executive Vice President, General Counsel

 

 

 

 

 

 

 

DOUGLAS E. DONLEY

 

 

 

 

 

 

 

 

/s/ Douglas E. Donley

 




Exhibit 10.5

AMENDMENT NO. 3 TO

EMPLOYMENT AGREEMENT

 

THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT, by and between Rite Aid Corporation, a Delaware Corporation (the “Company”) and Robert G. Miller (“Executive”) is entered into as of the 23rd day of December, 2008.  The provisions of this Amendment shall be effective as of January 1, 2005 (the “Effective Date”).

 

WHEREAS, Executive and the Company previously entered into that certain employment agreement, dated as of April 9, 2003, and subsequently amended on April 28, 2005 and March 28, 2008 (collectively, the “Employment Agreement”); and

 

WHEREAS, the Company and the Executive now desire to amend the Employment Agreement to ensure compliance with Internal Revenue Code Section 409A and the final regulations promulgated thereunder;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

 

1.                                        New Section 9 .  Effective as of the Effective Date, the following new Section 9 shall be inserted into the Employment Agreement.  In the event of an inconsistency between this new Section 9 and the remaining provisions of the Employment Agreement, Section 9 shall govern.

 

“9.                                  COMPLIANCE WITH CODE SECTION 409A   Notwithstanding anything in this Employment Agreement to the contrary, effective as of January 1, 2005, the following provisions shall govern:  The provisions listed below are intended to be compliant with Internal Revenue Code Section 409A and the final regulations promulgated thereunder (‘409A’) as in effect on the date hereof and shall be construed to be so compliant.

 

(a)                                   Good Reason: Any termination for ‘Good Reason’ is intended to comply with the safe harbor definition of ‘good reason’ in 409A, including the condition giving rise to such termination and the notice and cure period provided for in 409A.  In connection therewith, the following specific provisions will be effective as of January 1, 2005:

 

(i)                                      Section 4(c)(A)(i) of the Agreement shall be modified by inserting the word ‘material’ at the beginning thereof.

 

(ii)                                   Section 4(c)(A)(iii) of the Agreement shall be modified by deleting the parenthetical at the end thereof.

 



 

(iii)                                Section 4(c)(E) of the Agreement shall be modified to read as follows:

 

“E.                                 any other material breach of the Original Employment Agreement or this Agreement, as applicable, by the Company; provided, however that the Executive has provided notice to the Company of the existence of any condition described in any one of subparagraphs A, B, C, D or E within 90 days of the initial existence of such condition to the extent then known by the Executive by giving the Company a written notice (the “Notice of Termination for Good Reason”), setting forth in reasonable detail the specific conduct of the Company which constitutes Good Reason and the specific provisions of this Agreement on which the Executive relies, provided, that Executive’s continued employment shall not be deemed consent to, or a waiver of rights with respect to, any act, omission or other grounds constituting Good Reason hereunder.  For clarity, it is understood that the requirement of setting forth such specific conduct is intended (i) to permit the Company to make a reasonable evaluation of Executive’s claim of termination for Good Reason and (ii) to permit the Company to cure such conduct to the extent curable.  The Company shall have 30 days from the receipt of the Notice of Termination for Good Reason to cure the condition giving rise to the Good Reason.  Any termination of employment by the Executive under this paragraph must occur no later than the date that is the second anniversary of the initial existence of the condition giving rise to the termination right.’

 

(iv)                               Section 4(c)(ii) is hereby amended in its entirety to read as follows:

 

‘(ii)                               Any termination of employment by Executive within a six month period commencing on the date of a Change in Control of the Company (as defined in Section 8) shall not be treated as a termination of the Executive for Good Reason, however, it shall entitle the Executive to all benefits described in Section 5(a) as if the Executive had terminated for Good Reason.  However, the provisions of Section 9(c) of this Agreement shall apply to the payment of all such benefits.’

 

(b)                                  Medical Benefits :  The provision of medical benefits after separation from service shall be done in a manner to, to the extent

 



 

possible, exempt such benefits from the application of 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5(a)(2) and 5(b)(2) of the Agreement shall be modified by adding the following to the end thereof:

 

‘For any period during which the Executive would be entitled to continuation coverage through the application of Internal Revenue Code Section 4980B (‘COBRA’), this coverage shall be provided at the expense of the Company.  For any period after the expiration of the period required by COBRA, but prior to the end of the month in which the third anniversary of the Date of Termination occurs, this coverage will be provided at the expense of the Executive (or his beneficiaries or estate).  Executive (or his beneficiaries or estate) shall remit payment by check to the Company in the amount of the then current amount used to calculate premiums for participants entitled to receive continuation coverage under COBRA.  The Company shall, on the last day of each month, provide the Executive (or his beneficiaries or estate) with a payment sufficient to place the Executive (or his beneficiaries or estate) in the same economic position had such individuals or entity not been required to pay the premium described in the preceding sentence.’

 

(c)                                   Payment of Benefits : Any payment to which the Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon the Executives termination; (b) at a time when the Executive is a “specified employee” as defined by 409A shall not be made if necessary to comply with the requirements of clause (a)(2)(B)(i) of 409A until the earliest of:

 

(1)                                   the expiration of the six month period (the “Deferral Period”) measured from the date of the Executive’s “separation from service” under 409A; or

(2)                                   the date of the Executive’s death.

 

Upon the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to the Executive or, if applicable, his beneficiary.

 



 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5(d)(1) of the Agreement shall be amended by inserting the following language at the end thereof:

 

“Effective as of January 1, 2005, the provisions of Section 9(c) shall apply to payments made under this Section. To the extent permissible by law, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment’

 

(d)                                  Reimbursements :  To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:

 

(1)                                   The right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit;

(2)                                   The amount of expenses or in kind benefits available or paid in one year shall not affect the amount available or paid in any subsequent year; and

(3)                                   Such payments shall be made on or before the last day of the Executive’s taxable year in which the expense occurred.

 

2.                                        Employment Agreement to Remain in Effect .       Except as modified by this Amendment No. 3, the Employment Agreement shall remain in full force and effect in accordance with its terms.  Except to the extent explicitly required by 409A, nothing herein is intended to nor shall be construed to reduce any material benefit of Executive under the Employment Agreement or to require any repayment or reduction of any benefit provided to Executive prior to the date hereof.  In the event of a conflict between the provisions of this Amendment No. 3 and the Employment Agreement, this Amendment No. 3 shall be controlling.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

By:

/s/ Robert B. Sari

 

 

Robert B. Sari

 

 

EVP, General Counsel

 

 

 

 

 

Robert G. Miller

 

 

 

 

 

/s/ Robert G. Miller

 




Exhibit 10.6

 

AMENDMENT NO. 3 TO

EMPLOYMENT AGREEMENT

 

THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT, by and between Rite Aid Corporation, a Delaware Corporation (the “Company”) and Mary F. Sammons (“Executive”) is entered into as of the 30th day of December, 2008.  The provisions of this Amendment shall be effective as of January 1, 2005 (the “Effective Date”).

 

WHEREAS, Executive and the Company previously entered into that certain employment agreement, dated as of December 5, 1999, and subsequently amended on May 7, 2001 and September 30, 2003 (collectively, the “Employment Agreement”); and

 

WHEREAS, the Company and the Executive now desire to amend the Employment Agreement to ensure compliance with Internal Revenue Code Section 409A and the final regulations promulgated thereunder;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

 

1.                                        New Section 14 .  Effective as of the Effective Date, the following new Section 14 shall be inserted into the Employment Agreement.  In the event of an inconsistence between this new Section 14 and the remaining provisions of the Employment Agreement, Section 14 shall govern.

 

“14.                            COMPLIANCE WITH CODE SECTION 409A   Notwithstanding anything in this Employment Agreement (the “Agreement”) to the contrary, effective as of January 1, 2005, the following provisions shall govern:  The provisions listed below are intended to be compliant with Internal Revenue Code Section 409A and the final regulations promulgated thereunder (‘409A’) as in effect on the date hereof and shall be construed to be so compliant.

 

(a)                                   Medical Benefits :  The provision of medical benefits after separation from service shall be done in a manner to, to the extent possible, exempt such benefits from the application of 409A.  Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

(i)                                      Section 5(a)(2) and 5(b)(2) of the Agreement shall be modified by adding the following to the end of each thereof:

 



 

‘For any period during which the Executive would be entitled to continuation coverage through the application of Internal Revenue Code Section 4980B (‘COBRA’), this coverage shall be provided at the expense of the Company.  For any period after the expiration of the period required by COBRA, but prior to the end of the month in which the third anniversary of the Date of Termination occurs, this coverage will be provided at the expense of the Executive (or her beneficiaries or estate).  Executive (or her beneficiaries or estate) shall remit payment by check to the Company in the amount of the then current amount used to calculate premiums for participants entitled to receive continuation coverage under COBRA; provided, however, if the coverage is not available through the Company’s benefit plans, then Executive shall purchase and pay the premium for medical coverage substantially comparable in all material respects to the coverage provided by the Company during the COBRA period.  The Company shall, on the last day of each month, provide the Executive (or her beneficiaries or estate) with a payment sufficient to place the Executive (or her beneficiaries or estate) in the same economic position had such individuals or entity not been required to pay the premium described in the preceding sentence.’

 

(b)                                  Payment of Benefits : Any payment to which the Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon the Executive’s termination and; (b) at a time when the Executive is a “specified employee” as defined by 409A shall not be made if necessary to comply with the requirements of clause (a)(2)(B)(i) of 409A until the earliest of:

 

(1)                                   the expiration of the six month period (the “Deferral Period”) measured from the date of the Executive’s ‘separation from service’ under 409A; or

(2)                                   the date of the Executive’s death,

 

provided one or more exceptions to 409A that would allow for an earlier payment is not available.  The maximum payment allowable under all such exceptions combined will be made on the date provided under the Agreement prior to this Amendment No. 3.

 

Upon the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a

 



 

single lump sum or in installments) shall be paid as a single lump sum together with interest at the money market fund rate of the Company’s investments from time to time to the Executive or, if applicable, his beneficiary.

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5(d)(1) of the Agreement shall be modified by adding the following to the end thereof:

 

‘The provisions of Section 14(b) will apply to payments made under this Section 5(d)(1).  To the extent permissible by law, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment’

 

(c)                                   Reimbursements :  To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:

 

(1)                                   The right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit;

(2)                                   The amount of expenses or in kind benefits available or paid in one year shall not affect the amount available or paid in any subsequent year; and

(3)                                   Such payments shall be made on or before the last day of the Executive’s taxable year in which the expense occurred.

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 3(c) of the Agreement shall be modified to insert the following sentence at the end thereof:

 

‘The provisions of Section 14(c) shall apply to all reimbursements made under this Section 3(c)’

 

(d)                                  Gross Ups .  To the extent required by 409A, any ‘gross up’ payment shall be made no later than the end of the Executive’s taxable year following the year in which the employee remits the related taxes .

 

Without limiting the generality of the foregoing, the following specific provisions will be effective as of January 1, 2005:

 

Section 5 shall be amended by adding the following new Section 5(e)(v) immediately following Paragraph (iv) therof:

 



 

‘(v)                              The provisions of Section 14(d) shall apply to all payments made under this Section 5(e)’”

 

2.                                        Employment Agreement to Remain in Effect .       Except as modified by this Amendment No. 3, the Employment Agreement shall remain in full force and effect in accordance with its terms. Except to the extent explicitly required by 409A, nothing herein is intended to nor shall be construed to reduce any material benefit of Executive under the Employment Agreement or to require any repayment or reduction of any benefit provided to Executive prior to the date hereof.   In the event of a conflict between the provisions of this Amendment No. 3 and the Employment Agreement, this Amendment No. 3 shall be controlling.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

By:

/s/ Robert B. Sari

 

 

Robert B. Sari

 

 

Executive Vice President,

 

 

General Counsel

 

 

 

 

 

Mary F. Sammons

 

 

 

/s/ Mary F. Sammons

 




Exhibit 10.7

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into and effective as of the 3rd day of December, 2008 (the “Effective Date”) by and between Rite Aid Corporation, a Delaware corporation (the “Company”) and Ken Martindale (the “Executive”).

 

WHEREAS , Executive desires to provide the Company with his services and the Company desires to hire and employ Executive on the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE , in consideration of the mutual representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive (individually a “Party” and together the “Parties”), intending to be legally bound, agree as follows:

 

1.              Term of Employment .

 

The term of Executive’s employment under this Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to Section 5 below, shall continue for a period ending on the date that is two (2) years following the Effective Date (the “Original Term of Employment”).  The Original Term of Employment shall be automatically renewed for successive one year terms (the “Renewal Terms”) unless at least 180 days prior to the expiration of the Original Term of Employment or any Renewal Term, either Party notifies the other Party in writing that he or it is electing to terminate this Agreement at the expiration of the then current Term of employment “Term” shall mean the Original Term of Employment and all Renewal Terms.  For purposes of this Agreement, except as otherwise provided herein, the phrase “year during the Term” or similar language shall refer to each 12 month period commencing on the Effective Date or applicable anniversaries thereof.

 

2.              Position and Duties .

 

2.1           Generally.  During the Term, Executive shall serve as Senior Executive Vice President, Chief Merchandising, Marketing and Logistics Officer of the Company and shall have the titles, duties, responsibilities and authority as are customary for such positions and such other titles, duties, responsibilities and authorities as shall be assigned by the Company from time to time consistent with such positions.  Executive shall devote his full working time, attention, knowledge and skills faithfully and to the best of his ability, to the duties and responsibilities assigned by the Company in furtherance of the business affairs and activities of the Company and its subsidiaries, affiliates and strategic partners.  Executive shall report solely to the Company’s President and/or Chief Operating Officer and/or Chief Executive Officer and/or Board of Directors.  Following

 



 

termination of Executive’s employment for any reason, Executive shall immediately resign from all offices and positions he holds with the Company or any subsidiary.

 

Other than necessary travel in connection with the performance of his duties hereunder, the Executive shall be based at the Company’s headquarters.

 

2.2           Other Activities .   Anything herein to the contrary notwithstanding, nothing in this Agreement shall preclude the Executive from engaging in the following activities:  (i) serving on the board of directors of a reasonable number of other corporations or the boards of a reasonable number of trade associations and/or charitable organizations, subject to the Company’s approval, which shall not be unreasonably withheld, with the current activities listed on Appendix D being approved; (ii) engaging in charitable activities and community affairs; and (iii) managing his personal investments and affairs, provided that such activities do not violate Sections 6 or 7 below or materially interfere with the proper performance of his duties and responsibilities under this Agreement.  Executive shall at all times be subject to, observe and carry out such lawful rules, regulations, policies, directions, and restrictions as the Company may from time to time establish for officers of the Company.

 

3.              Compensation .

 

3.1           Base Salary During the Term, as compensation for his services hereunder, Executive shall receive a base salary at the annualized rate of $600,000.00 per year (“Base Salary” as shall be reviewed annually for possible increase), which shall be paid in accordance with the Company’s normal payroll practices and procedures, less such deductions or offsets required by applicable law or otherwise authorized by Executive.

 

3.2           Annual Performance Bonus .  The Executive shall participate each fiscal year during the Term in the Company’s annual bonus plan as adopted and approved by the Board or the Compensation Committee from time to time.  For the current fiscal year (Fiscal Year 2009), Executive’s annual bonus opportunity pursuant to such plan shall equal 100% (the “Annual Target Bonus”) of the annualized Base Salary ($600,000 per year for Fiscal Year 2009) even though the entire $600,000 Base Salary for Fiscal Year 2009 will not be paid to Executive as a result of this Agreement.  For subsequent fiscal years, the Annual Target Bonus may be adjusted (however, in no event shall it be less than 100%) and shall be based upon the Board approved plan for that year.

 

3.3           Equity Awards .

 

(a)            On the Effective Date, the Executive will be granted an option (the “Option”) to purchase 1,000,000 shares of the Company’s Common Stock, par value $1.00 per share (“Company Stock”).  The Option shall:  (i) be a nonqualified stock option; (ii) have an exercise price equal to the closing price of the Company Stock as reported on the New York Stock Exchange (“NYSE “) on the date of grant; (iii) have a term of ten (10) years following the date of grant; (iv) vest and become exercisable as to

 



 

one-fourth of the shares of the Company Stock subject to the option on each of the first four (4) anniversaries from the date of grant; (v) be subject to the acceleration exercise and termination provisions set forth in Section 3.3(c) and Article 5 hereof; and (vi) otherwise be evidenced by and subject to the terms of the Company’s stock option and equity plans.

 

(b)            At a meeting of the Compensation Committee of the Board of Directors prior to or on the Effective Date and subject to the approval of the Compensation Committee, Executive will be recommended for participation in the Company’s Executive Equity Plan (the “EEP”).  On a going forward basis, the award will be based upon Executive’s annual Base Salary and the stock closing price on the date of grant.  For the current fiscal year (FY 2009) only, Executive’s participation in the EEP will be on a prorated basis.

 

(c)            Upon the occurrence of a Change in Control of the Company and prior to the termination of Executive’s employment with the Company, the Options awarded pursuant to subsection (a) above then held by Executive shall immediately vest and become exercisable in full.  For purposes of this Agreement “Change in Control” shall have the meaning set forth in the attached Appendix A.

 

(d)            It is understood and acknowledged by Executive that the securities underlying the stock options and/or restricted stock that may be awarded to Executive from time to time may not be subject to an effective registration statement under the federal securities laws until some time after the Effective Date.  The Company agrees that if, as of the date of termination of Executive’s employment under the circumstances described in Sections 5.2 (except termination for Cause), 5.3 and 5.5, the securities underlying the then vested and exercisable portion of any stock options are not subject to an effective registration statement, the ninety (90) day periods in Section 5.2 (except termination for Cause), 5.3 and 5.5, as applicable, will be deemed to run from the first date such securities become subject to an effective registration statement.

 

4.              Additional Benefits .

 

4.1       Employee Benefits During the Term, Executive and, as to welfare plans the Executive’s eligible immediate family, as the case may be, shall be entitled to participate in the employee benefit plans (including, but not limited to medical, dental and life insurance plans, short-term and long-term disability coverage, the Supplemental Executive Retirement Plan (which shall be at the monthly contribution rate equal to 2% of Executive’s Base Salary) and 401(k) plans) in which senior management employees of the Company are generally eligible to participate, subject to any eligibility requirements and the other generally applicable terms of such plans.

 

4.2       Expenses During the Term, the Company shall reimburse Executive for any expenses reasonably incurred by him in furtherance of his duties hereunder, including without limitation travel, meals and accommodations, upon submission of vouchers or receipts and in compliance with such rules and policies relating thereto as the

 



 

Company may from time to time adopt or as may be required in order to permit such payments to be taken as proper deductions by the Company or any subsidiary under the Internal Revenue Code of 1986, as amended, and the rules and regulations adopted pursuant thereto now or hereafter in effect.

 

4.3       Vacation Executive shall be entitled to four (4) weeks paid vacation during each year of the Term.

 

4.4       Automobile Allowance .   During the Term, the Company shall provide Executive with an automobile allowance of $1,000.00 per month.

 

4.5       Annual Financial Planning Allowance .   During each year of the Term, the Company shall provide Executive with an executive planning allowance in the amount of up to $5,000.00.

 

4.6       Relocation Benefits Subject to Executive providing reasonable documentation to Company, the Company shall reimburse Executive up to a total of $200,000 for transportation, commuting, lodging and other relocation expenses (including but not limited to moving, house hunting trips and other direct costs incurred in connection with Executive’s relocation) incurred by Executive for a period of up to thirty-six (36) months from the Effective Date (collectively, the “Relocation Benefits Payments”) To the extent the Relocation Benefits Payments are subject to federal, state or local income tax payments by Executive, Company shall also pay to Executive an additional amount (the “Gross-Up Payment”) such that the net amount retained by the Executive, after deduction of the applicable federal, state and local income taxes upon the Gross-Up Payment shall be equal to the total Relocation Benefits Payments.

 

4.7           Indemnification The Company shall (a) indemnify and hold Executive harmless, to the full extent permitted under applicable law, for, from and against any and all losses, claims, costs, expenses, damages, liabilities or actions (including security holder actions, in respect thereof) relating to or arising out of the Executive’s employment with and service as an officer of the Company or as an officer or director of an entity other than the Company at the request of the Company; and (b) pay all reasonable costs, expenses and attorney’s fees incurred by Executive in connection with or relating to the defense of any such loss, claim, cost, expense, damage, liability or action, subject to Executive’s undertaking to repay in the event it is ultimately determined that Executive is not entitled to be indemnified by the Company and enforcement of its rights hereunder.  Following termination of the Executive’s employment or service with the Company, the Company shall cause any Director and Officer liability insurance policies applicable to the Executive prior to such termination to remain in effect for six (6) years following the date of termination of employment.

 



 

5.              Termination .

 

5.1           Termination of Executive’s Employment by the Company for Cause .   The Company may terminate Executive’s employment hereunder for Cause (as defined below).  Such termination shall be effected by written notice thereof delivered by the Company to Executive, indicating in reasonable detail the facts and circumstances alleged to provide a basis for such termination, and shall be effective as of the date of such notice in accordance with Section 12 hereof.  “Cause” as determined in reasonable good faith by a resolution adopted by the affirmative vote of a majority of the Company’s Board of Directors (after reasonable written notice to Executive setting forth in reasonable detail the specific conduct of Executive upon which the Board relies in reaching its determination, and a reasonable opportunity for Executive, together with his counsel, to be heard before the Board prior to making such determination) shall mean:  (i) Executive’s gross negligence or willful misconduct in the performance of the duties or responsibilities of his position with the Company or any subsidiary, or failure to timely carry out any lawful and reasonable directive of the President, Chief Operating Officer, Chief Executive Officer or Board of Directors; (ii) Executive’s intentional misappropriation of any funds or property of the Company or any subsidiary; (iii) the conduct by Executive which is a material violation of this Agreement or written Company Policy which materially interferes with the Executive’s ability to perform his duties; provided, however, that Executive shall have the right, within thirty (30) days after receipt of written notice (which shall set forth in reasonable detail the specific conduct of Executive that constitutes Cause and the specific provision(s) of this Agreement on which Company relies) from Company of the Executive’s violation of this subsection, to cure the event or circumstances giving rise to such Cause and in the event of which cure, such event or circumstances shall not constitute Cause hereunder; (iv) the commission by Executive of an act of fraud, misappropriation or embezzlement toward the Company or any subsidiary; (v) Executive’s gross negligence or willful misconduct which damages or injures the Company or the Company’s reputation; (vi) Executive is convicted of or pleads guilty to a felony involving moral turpitude; or (vii) the use or imparting by Executive of any confidential or proprietary information of the Company, or any subsidiary in material violation of Section 6 below.

 

5.2           Compensation Upon Termination by the Company for Cause or by Executive Without Good Reason .   In the event of Executive’s termination of employment (i) by the Company for Cause or (ii) by Executive voluntarily without Good Reason:

 

(a)            Executive shall be entitled to receive within ten (10) business days of the date of termination:  (i) all amounts of accrued but unpaid Base Salary through the effective date of such termination; (ii) reimbursement for reasonable and necessary expenses incurred by Executive through the date of such termination, to the extent otherwise provided under Section 4.2 above; (iii) all other vested payments and benefits to which Executive may otherwise be entitled pursuant to the terms of the applicable benefit plan or arrangement through the effective date of such termination; and (iv) reimbursement of Relocation Benefits Payments incurred prior to the date of termination

 



 

((i), (ii), (iii) and (iv), the (“Accrued Benefits”).  All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in this subsection (a) or (b) below.

 

(b)            Except as provided in Section 3.3(d), any portion of any restricted stock or any other equity incentive awards as to which the restrictions have not lapsed or as to which any other conditions shall not have been satisfied prior to the date of termination shall be forfeited as of such date and any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or, such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate; provided, however, in the event of termination of Executive by the Company for Cause, any stock options that have not been exercised prior to the date of termination shall immediately terminate as of such date.

 

Any termination of Executive’s employment by Executive voluntarily without Good Reason shall be effective upon thirty (30) days’ notice to the Company or such earlier date as the Company determines in its discretion and designates in writing.  A termination of Executive’s employment by the Company for Cause or by the Executive other than for Good Reason shall not constitute a breach of this Agreement.

 

5.3           Compensation Upon Termination of Executive’s Employment by the Company Other Than for Cause or by Executive for Good Reason .   Executive’s employment hereunder may be terminated by the Company other than for Cause or by Executive for Good Reason.  In the event that Executive’s employment hereunder is terminated by the Company other than for Cause or by Executive for Good Reason:

 

(a)            Executive shall be entitled to receive:  (i) within ten (10) business days of the date of termination the Accrued Benefits; (ii) an amount equal to two times the sum of Executive’s then Base Salary plus Annual Target Bonus as of the date of termination of employment, such amount payable in equal installments pursuant to the Company’s standard payroll procedures for management employees over a period of two (2) years following the date of termination of employment; and (iii) continued health and medical insurance coverage (or reimbursement to Executive of the cost of purchasing health and medical coverage substantially comparable in all material respects to the coverage provided by the Company to the Executive, excepting payments for such periods that the Company provides such coverage) for Executive and his immediate family for a period of two (2) years following the date of termination of employment.  In addition, if such termination occurs following the start of the Company’s fiscal year, Executive shall also be entitled to receive (which shall be paid at the same time paid to other eligible participants in the bonus plan and following determination by the Board that the Company has achieved or exceeded its annual performance targets for the fiscal

 



 

year) a pro rata annual bonus determined by multiplying Executive’s then Annual Target Bonus by a fraction (x) the numerator of which is the number of days between the beginning of the then current fiscal year of the Company and the date of termination of employment and (y) the denominator of which is 365.

 

(b)            The Executive’s stock option awards held by Executive shall vest and become immediately exercisable and the restrictions with respect to any awards of restricted stock shall lapse, in each case to the extent such options would otherwise have become vested and exercisable (or such restrictions would have lapsed) had Executive remained in the employ of the Company for a period of two years following the date of termination.  Except as provided in Section 3.3(d), such portion of Executive’s stock options (together with any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination) shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate.  Any remaining portion of Executive’s stock options that have not vested (or deemed to have vested) as of the date of termination shall terminate as of such date; and all shares of restricted stock as to which the restrictions shall not have lapsed (or deemed to have lapsed) as of the date of termination shall be forfeited as of such date.

 

(c)            All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in 5.3(a) through (c).

 

Any termination of employment pursuant to this Section 5.3 shall be effective upon thirty (30) days notice thereof or the Company may elect in its sole discretion to reduce or eliminate the notice period and pay the Executive his base salary for some or all of the notice period in lieu of notice, prorated as applicable.  A termination of Executive’s employment by the Company other than for Cause or by the Executive for Good Reason shall not constitute a breach of this Agreement.  To be eligible for the payment, benefits and stock rights described in Section 5.3(a)(ii)-(iii), (b) and (c) above, Executive must execute, not revoke and abide by a release (which shall be substantially in the form attached hereto as Appendix C) of all other claims, reasonably cooperate (subject to reimbursement by Company of reasonable costs and expenses incurred by Executive) with the Company in the event of litigation (other than by Executive) involving the Company and fully comply in all material respects with Executive’s obligations under Sections 6 and 7 below.

 

5.4           Definition of Good Reason For purposes of this Agreement, “Good Reason” shall mean the occurrence of any one of the following:

 



 

(a)            any adverse alteration in Executive’s titles, position, status, duties, authorities, reporting relationship or responsibilities with the Company or its subsidiaries from those specified in this Agreement; or

 

(b)            any decrease in Executive’s then Base Salary as set forth in Section 3.1 or Annual Target Bonus in Section 3.2 to which Executive has not agreed in writing; or

 

(c)            any other material breach by the Company of this Agreement; or

 

(d)            failure to promptly provide any material benefits hereunder;

 

provided, however, that in each such case the Company shall have the right, within thirty (30) days (fifteen (15) days for the payment of compensation under this Agreement) after receipt of written notice (which shall set forth in reasonable detail the specific conduct of Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive relies) from Executive of the Company’s violation of any of the foregoing, to cure the event or circumstances giving rise to such Good Reason and in the event of which cure, such event or circumstances shall not constitute Good Reason hereunder.

 

5.5           Compensation Upon Termination of Executive’s Employment by Reason of Executive’s Death or Total Disability In the event that Executive’s employment with the Company is terminated by reason of Executive’s death or Total Disability (as defined below):

 

(a)            Executive or Executive’s estate, as the case may be, shall be entitled to receive:  (i) within ten (10) business days of the date of termination the Accrued Benefits; (ii) promptly any other benefits payable under the then current disability and/or death benefit plans, as applicable, in which Executive is a participant; and (iii) continued health and medical insurance coverage (or reimbursement to Executive of the cost of purchasing health and medical coverage substantially comparable in all material respects to the coverage provided by the Company to the Executive, excepting payments for such periods that the Company provides such coverage) for Executive and/or his immediate family, as applicable, for a period of two (2) years following the date of termination of employment.  In addition, if such termination occurs following the start of the Company’s fiscal year, Executive shall also be entitled to receive (which shall be paid at the same time paid to other eligible participants in the bonus plan and following determination by the Board that the Company has achieved or exceeded its annual performance targets for the fiscal year) a prorata annual bonus determined by multiplying Executive’s then Annual Target Bonus by a fraction (x) the numerator of which is the number of days between the beginning of the then current fiscal year of the Company and the date of termination of employment and (y) the denominator of which is 365.

 



 

(b)            All stock option awards held by Executive shall vest and become immediately exercisable and the restrictions with respect to any awards of restricted stock shall lapse, in each case to the extent such options would otherwise have become vested and exercisable (or such restrictions would have lapsed) had Executive remained in the employ of the Company for a period of two (2) years following the date of termination.  Except as provided in Section 3.3(d) such portion of Executive’s stock options (together with any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination) shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or, such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate.  Any remaining portion of Executive’s stock options that have not vested (or deemed to have vested) as of the date of termination shall terminate as of such date; and all shares of restricted stock as to which the restrictions shall not have lapsed as of the date of termination shall be forfeited as of such date.

 

(c)            All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in Section 5.5(a) through (c).

 

“Total Disability” shall mean any physical or mental disability that prevents Executive from:  (a) (i) performing one or more of the essential functions of his position for a period of not less than 150 days in any twelve (12) month period; and (ii) which is expected to be of permanent or indeterminate duration but expected to last at least twelve (12) continuous months or result in death of the Executive as determined (y) by a physician selected by the Company or its insurer or (z) pursuant to the Company’s benefit programs; or (b) reporting to work for ninety (90) or more consecutive business days or unable to engage in any substantial activity.

 

5.6           Survival In the event of any termination of Executive’s employment, Executive and the Company nevertheless shall continue to be bound by the terms and conditions set forth in Section 4.7 above, 5.7 and 5.9 below and Sections 6 through 10 below, which shall survive the expiration of the Term.

 

5.7           Excise Tax Gross-Up .

 

(a)            In the event that any payment or benefit received or to be received by the Executive pursuant to the terms of this Agreement or any other plan, arrangement or agreement of the Company (or any affiliate) (collectively, the “Payments”) would be subject to the Excise Tax (the “Excise Tax”) imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), as determined as provided below, the Company shall pay to the Executive, at the time specified in Section 5.7(b) below an additional amount (the “Gross-Up Payment”) such that the net amount retained by the Executive, after deduction of the Excise Tax on payments and any federal, state and local

 


 

income and employment or other tax and the Excise Tax upon the Gross-Up Payment, and any interest, penalties or additions to tax payable by the company Executive with respect thereto, shall be equal to the total Payments.  For purposes of determining whether any of the Payments will be subject to the Excise Tax and the amounts of such Excise Tax, (1) the total amount of the Payments shall be treated as “parachute payments” within the meaning of section 280G(b)(2) of the Code, and all “excise parachute payments” within the meaning of section 280G(b)(1) of the Code shall be treated as subject to the Excise Tax, except to the extent that, in the opinion of tax counsel (“Tax Counsel”) reasonably acceptable to Executive and selected by the Company, a Payment (in whole or in part) does not constitute a “parachute payment” within the meaning of section 280G(b)(2) of the Code, or such “excess parachute payments” (in whole or in part) are not subject to the Excise Tax, (2) the amount of the Payments that shall be treated as subject to the Excise Tax shall be equal to the lesser of (A) the total amount of the Payments or (B) the amount of “excess parachute payments” within the meaning of section 280G(b)(1) of the Code (after applying clause (1) hereof), and (3) the value of any noncash benefits or any deferred payment or benefit shall be determined by the Tax Counsel in accordance with the principles of sections 280G(d)(3) and (4) of the Code.  For purposes of determining the amount of the Gross-Up Payment, the Executive shall be deemed to pay federal income taxes at the highest marginal rates of federal income taxation applicable to individuals in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rates of taxation applicable to individuals as are in effect in the state and locality of the Executive’s residence in the calendar year in which the Gross-Up Payment is to be made, net of the maximum reduction in federal income taxes that can be obtained from deduction of such state and local taxes, taking into account any limitations applicable to individuals subject to federal income tax at the highest marginal rates.

 

(b)             The Gross-Up Payment provided for in Section 5.7(a) hereof shall be made upon the earlier of (i) thirty (30) days following the date of termination of Executive’s employment or (ii) the imposition upon the Executive or payment by the Executive of any Excise Tax.

 

(c)             If it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding that the Excise Tax is less than the amount taken into account under Section 5.7(a) hereof, the Executive shall repay to the Company within thirty (30) days of the Executive’s receipt of notice of such final determination the portion of the Gross-Up Payment attributable to such reduction (plus the portion of the Gross-Up Payment attributable to the Excise Tax and federal, state and local income tax imposed on the portion of the Gross-Up Payment being repaid by the Executive if and to the extent that such repayment results in a reduction in Excise Tax and a dollar for dollar reduction in the Executive’s taxable income and wages for the purpose of federal, state and local income taxes) plus any interest received by the Executive on the amount of such repayment.  If it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding that the Excise Tax exceeds the amount taken into account hereunder (including without limitation by reason of any payment the existence or amount of which cannot be determined at the time of the Gross-Up Payment), the

 



 

Company shall make an additional Gross-Up Payment pursuant to Section 5.7(a) in respect of such excess within thirty (30) days of the Company’s receipt of notice of such final determination or proceeding.  The Executive and the Company shall each reasonably cooperate with the other in connection with any administrative or judicial proceedings concerning the existence or amount of liability for Excise Tax with respect to the Payments.

 

(d)            In the event of any change in, or further interpretation of, sections 280G or 4999 of the Code and the regulations promulgated thereunder, the Executive shall be entitled, by written notice to the Company, to request an opinion of Tax Counsel regarding the application of such change to any of the foregoing, and the Company shall use its best efforts to cause such opinion to be rendered as promptly as practicable.  All fees and expenses of the Tax Counsel incurred in connection with this Agreement shall be borne by the Company.

 

5.8            No Other Severance or Termination Benefits Except as expressly set forth herein, Executive shall not be entitled to damages or to any severance or other benefits upon termination of employment with the Company under any circumstances and for any or no reason, including, but not limited to any severance pay under any Company severance plan, policy or practice.

 

5.9            Section 409A .  Notwithstanding anything in this Agreement to the contrary, to the extent:  (a) that any payment to which the Executive becomes entitled under this Agreement (including, without limitation, any payments made pursuant to this Clause), or any agreement or plan referenced herein, in connection with the Executive’s termination of employment with the Company constitutes deferred compensation subject to Section 409A of the Code; and (b) the Executive is deemed at the time of such termination of employment to be a “specified employee” under Code Section 409A, such payment shall not be made or commence until the earliest of:  (i) the expiration of the six (6) month period measured from the date of the Executive’s “separation from service” (as such term is at the time defined in Treasury Regulations under Code Section 409A) with the Company; (ii) the date the Executive becomes “disabled” (as defined in Code Section 409A); or (iii) the date of the Executive’s death following such separation from service; provided, however, that such deferral shall only be effected if and to the extent required to avoid adverse tax treatment to the Executive, including, without limitation, those imposed under Code Section 409A(a)(1)(B) in the absence of such deferral; provided, however, that if the Company reasonably and in good faith determines, based upon and in accordance with advice from its outside counsel or tax advisors, that a deferral pursuant to this sentence is necessary, the Executive agrees that the Company will not be liable to the Executive for any damages to the Executive arising from such deferral of such payment.  Upon the expiration of the deferral period, any payments that would have otherwise been made during that period (whether in a single sum or in installments) shall be paid in a single cash lump sum payment to the Executive (or his beneficiary, as applicable).  With regard to any provision that provides for reimbursement of costs and expenses or of in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for

 



 

another benefit, (ii) the amount of expenses eligible for reimbursement or in-kind benefits to be provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year, provided that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect, and (iii) such payments shall be made on or before the last day of the Executive’s taxable year following the taxable year in which the expense occurred.  Each amount to be paid or benefit to be provided to the Executive shall be construed as a “separate identified payment” for purposes of Code Section 409A to the fullest extent permitted therein.

 

6.              Protection of Confidential Information .

 

Executive acknowledges that during the course of his employment with the Company, its subsidiaries, affiliates and strategic partners, he will be exposed to documents and other information regarding the confidential affairs of the Company, its subsidiaries, affiliates and strategic partners, including without limitation information about their past, present and future financial condition, pricing strategy, prices, suppliers, cost information, business and marketing plans, the markets for their products, key personnel, past, present or future actual or threatened litigation, trade secrets and other intellectual property, current and prospective customer lists, operational methods, acquisition plans, prospects, plans for future development and other business affairs and information about the Company and its subsidiaries, affiliates and strategic partners not readily available to the public (the “Confidential Information”).  Executive further acknowledges that the services to be performed under this Agreement are of a special, unique, unusual, extraordinary and intellectual character.  In recognition of the foregoing, the Executive covenants and agrees as follows:

 

6.1           No Disclosure or Use of Confidential Information At no time shall Executive ever divulge, disclose, or otherwise use any Confidential Information (other than as necessary to perform his duties under this Agreement and in furtherance of the Company’s best interests or as otherwise required by law, regulation or legal process or with respect to a lawsuit with the Company, its affiliates, subsidiaries or parents), unless and until such information is readily available in the public domain by reason other than Executive’s disclosure or use thereof in violation of the first clause of this Section 6.1.  Executive acknowledges that Company is the owner of, and that Executive has no rights to, any trade secrets, patents, copyrights, trademarks, know-how or similar rights of any type, including any modifications or improvements to any work or other property developed, created or worked on by Executive during the Term of this Agreement.

 

6.2            Return of Company Property, Records and Files Upon the termination of Executive’s employment at any time and for any reason, or at any other time the Board may so direct, Executive shall promptly deliver to the Company’s offices in Harrisburg, Pennsylvania all of the property and equipment of the Company, its subsidiaries, affiliates and strategic partners (including any cell phones, pagers, credit cards, personal computers, etc.) and any and all documents, records, and files, including

 



 

any notes, memoranda, customer lists, reports or any and all other documents, including any copies thereof, whether in hard copy form or on a computer disk or hard drive, which relate to the Company, its subsidiaries, affiliates, strategic partners, successors or assigns, and/or their respective past and present officers, directors, employees or consultants (collectively, the “Company Property, Records and Files”); it being expressly understood that, upon termination of Executive’s employment at any time and for any reason, Executive shall not be authorized to retain any of the Company Property, Records and Files, any copies thereof or excerpts therefrom.

 

7.              Noncompetition and Other Matters .

 

7.1            Noncompetition During the Executive’s employment with the Company and for the one (1) year period immediately following the date of termination of Executive’s employment (the “Restricted Period”) Executive shall not, directly or indirectly, in any city, town, county, parish or other municipality in any state of the United States (the names of each such city, town, parish, or other municipality, including, without limitation, the name of each county in the Commonwealth of Pennsylvania being expressly incorporated by reference herein), or any other place in the world, where the Company, or its subsidiaries, affiliates, strategic partners, successors, or assigns, engages in the ownership, management and operation of retail drugstores (i) engage in a Competing Business for Executive’s own account; (ii) enter the employ of, or render any consulting or contracting services to, any Competing Business; or (iii) become interested in or otherwise associated or connected with any Competing Business in any capacity, including, without limitation, as an individual, partner, shareholder, officer, director, principal, agent, trustee, employee, contractor, consultant or management position with any entity providing consulting services to a Competing Business; provided , however, Executive may (i) own, directly or indirectly, solely as a passive investment, securities of any entity traded on any national securities exchange if Executive is not a controlling person of, or a member of a group which controls such entity and does not, directly or indirectly, own 3% or more of any class of securities of such entity.  For purposes of this Section 7.1, the phrase “Competing Business” shall mean any entity a majority of whose business involves the ownership and operation of retail or internet based drugstores.

 

7.2            Noninterference .   During the Restricted Period , Executive shall not, directly or indirectly, solicit, induce, or attempt to solicit or induce any officer, director, employee, agent or consultant of the Company or any of its subsidiaries, affiliates, strategic partners, successors or assigns to terminate his, her or its employment or other relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for the purpose of associating with any competitor of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, or otherwise encourage any such person or entity to leave or sever his, her or its employment or other relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for any other reason.

 

7.3            Nonsolicitation During the Restricted Period, Executive shall not, directly or indirectly, solicit, induce, or attempt to solicit or induce any customers, clients,

 



 

vendors, suppliers or consultants then under contract to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, to terminate, limit or otherwise modify his, her or its relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, for the purpose of associating with any competitor of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, or otherwise encourage such customers, clients, vendors, suppliers or consultants then under contract to terminate his, her or its relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for any reason.  During the Restricted Period, Executive shall not hire, either directly or through any employee, agent or representative, any field and corporate management employee of the Company or any subsidiary or any such person who was employed by the Company or any subsidiary within 180 days of such hiring, provided, however, nothing herein shall prohibit any advertisement or general hiring as a result thereof that is not specifically targeted at such persons.

 

8.              Rights and Remedies Upon Breach .

 

If Executive breaches, or threatens to commit a breach of, any of the provisions of Sections 6 or 7 above (the “Restrictive Covenants”), the Company and its subsidiaries, affiliates, strategic partners, successors or assigns shall have the following rights and remedies, each of which shall be independent of the others and severally enforceable, and each of which shall be in addition to, and not in lieu of, any other rights or remedies available to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns at law or in equity.

 

8.1            Specific Performance .   The right and remedy to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction by injunctive decree or otherwise, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns and that money damages would not provide an adequate remedy to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns.

 

8.2           Accounting The right and remedy to require Executive to account for and pay over to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, as the case may be, all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive as a result of any transaction or activity constituting a material or intentional breach of any of the Restrictive Covenants.

 

8.3           Severability of Covenants Executive acknowledges and agrees that the Restrictive Covenants are reasonable and valid in geographic and temporal scope and in all other respects.  If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full force and effect without regard to the invalid portions.

 



 

8.4             Modification by the Court If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable because of the duration or scope of such provision, such court shall have the power (and is hereby instructed by the parties) to modify or reduce the duration or scope of such provision, as the case may be (it being the intent of the parties that any such modification or reduction be limited to the minimum extent necessary to render such provision enforceable), and, in its modified or reduced form, such provision shall then be enforceable.

 

8.5             Enforceability in Jurisdictions Executive intends to and hereby confers jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographic scope of such covenants.  If the courts of any one or more of such jurisdictions hold the Restrictive Covenants unenforceable by reason of the breadth of such scope or otherwise, it is the intention of Executive that such determination not bar or in any way affect the right of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns to the relief provided herein in the courts of any other jurisdiction within the geographic scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.

 

8.6             Extension of Restriction in the Event of Breach .  In the event that Executive breaches any of the provisions set forth in this Section 8, the length of time of the Restricted Period shall be extended for a period of time equal to the period of time during which Executive is in breach of such provision.

 

9.              No Violation of Third Party Rights Executive represents, warrants and covenants that he:

 

(i)             will not, in the course of employment, infringe upon or violate any proprietary rights of any third party (including, without limitation, any third party confidential relationships, patents, copyrights, mask works, trade secrets, or other proprietary rights);

 

(ii)             is not a party to any conflicting agreements with third parties, which will prevent him from fulfilling the terms of employment and the obligations of this Agreement;

 

(iii)            does not have in his possession any confidential or proprietary information or documents belonging to others and will not disclose to the Company, use, or induce the Company to use, any confidential or proprietary information or documents of others; and

 

(iv)           agrees to respect any and all valid obligations which he may now have to prior employers or to others relating to confidential information, inventions, discoveries or other intellectual property which are the property of those prior employers or others, as the case may be.

 



 

Executive has supplied to the Company a copy of each written agreement with any of Executive’s prior employers, as well as any other agreements to which Executive is subject, which includes any obligation of confidentiality, assignment of intellectual property, nonsolicitation or noncompetition.  Executive has listed each of such agreements in Appendix “B”.

 

Executive agrees to indemnify and save harmless the Company from any loss, claim, damage, cost or expense of any kind (including without limitation, reasonable attorney fees) to which the Company may be subjected by virtue of a breach by Executive of the foregoing representations, warranties, and covenants.

 

10.           Arbitration .

 

Except as necessary for the Company and its subsidiaries, affiliates, strategic partners, successors or assigns or Executive to specifically enforce or enjoin a breach of this Agreement (to the extent such remedies are otherwise available), the parties agree that any and all disputes that may arise in connection with, arising out of or relating to this Agreement, or any dispute that relates in any way, in whole or in part, to Executive’s employment with the Company or any subsidiary, affiliate or strategic partner, the termination of that employment or any other dispute by and between the parties or their subsidiaries, affiliates, strategic partners, successors or assigns, shall be submitted to final and binding arbitration in Harrisburg, Pennsylvania according to the National Employment Dispute Resolution Rules and procedures of the American Arbitration Association at the time in effect.  This arbitration obligation extends to any and all claims that may arise by and between the parties or their subsidiaries, affiliates, strategic partners, successors or assigns, and expressly extends to, without limitation, claims or causes of action for wrongful termination, impairment of ability to compete in the open labor market, breach of an express or implied contract, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, fraud, misrepresentation, defamation, slander, infliction of emotional distress, disability, loss of future earnings, and claims under the Pennsylvania Constitution, the United States Constitution, and applicable state and federal fair employment laws, federal and state equal employment opportunity laws, and federal and state labor statutes and regulations, including, but not limited to, the Civil Rights Act of 1964, as amended, the Fair Labor Standards Act, as amended, the Americans With Disabilities Act of 1990, as amended, the Rehabilitation Act of 1973, as amended, the Employee Retirement Income Security Act of 1974, as amended, the Age Discrimination in Employment Act of 1967, as amended, and any other state or federal law.  Executive understands that by entering into this Agreement, Executive is waiving Executive’s rights to have a court determine Executive’s rights, including under federal, state or local statutes prohibiting employment discrimination, including sexual harassment and discrimination on the basis of age, race, color, religion, national origin, disability, veteran status or any other factor prohibited by governing law.

 



 

11.            Assignment .

 

Neither this Agreement, nor any of Executive’s rights or obligations hereunder, may be assigned or otherwise subject to hypothecation by Executive, other than by will or the laws of the descent and distribution.  The Company may assign its rights and obligations hereunder, and Executive hereby consents to any such assignment, in whole or in part:  (i) to the Company’s parent corporation; or (ii) to any other successor or assign in connection with the sale of all or substantially all of the Company’s assets or stock or in connection with any merger, acquisition and/or reorganization involving the Company; provided, however, any such assignment will not diminish or waive any of Executive’s rights hereunder, including, without limitation, rights upon any Change in Control of the Company.

 

12.           Notices .

 

All notices and other communications under this Agreement shall be in writing and shall be given by fax or first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three (3) days after mailing or twenty-four (24) hours after transmission of a fax to the respective persons named below:

 

If to the Company:

Rite Aid Corporation

 

30 Hunter Lane

 

Camp Hill, PA 17011

 

Attention: General Counsel

 

Fax: (717) 760-7867

 

 

If to Executive:

Ken Martindale

 

at the most recent address on file at the Company’s payroll office

 

Any party may change such party’s address for notices by notice duly given pursuant hereto.

 

13.            General .

 

13.1         No Offset or Mitigation The Company’s obligation to make the payments provided for in, and otherwise to perform its obligations under this Agreement shall not be affected by any setoff, counterclaim, recoupment, defense or other claim, right or action that the Company may have against the Executive or others whether in respect of claims made under this Agreement or otherwise.  In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts, benefits and other compensation payable or otherwise provided to the Executive under any of the provisions of this Agreement, and such amounts shall not be reduced, regardless of whether the Executive obtains other employment.

 



 

13.2         Governing Law .  This Agreement is executed in Pennsylvania and shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Pennsylvania without giving effect to conflicts of laws principles thereof which might refer such interpretations to the laws of a different state or jurisdiction.  Any court action instituted by Executive relating in any way to this Agreement shall be filed exclusively in state or federal court in Harrisburg, Pennsylvania and Executive consents to the jurisdiction and venue of said courts in any action instituted by or on behalf of the Company against him.

 

13.3        Entire Agreement This Agreement sets forth the entire understanding of the parties relating to Executive’s employment with the Company and cancels and supersedes all agreements, arrangements and understandings relating thereto made prior to the date hereof, written or oral, between the Executive and the Company and/or any subsidiary or affiliate.

 

13.4        Amendments: Waivers This Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms or covenants hereof may be waived, only by a written instrument executed by the parties, or in the case of a waiver, by the party waiving compliance. The failure of any party at any time or times to require performance of any provision hereof shall in no manner affect the right of such party at a later time to enforce the same.  No waiver by any party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

 

13.5         Conflict with Other Agreements Executive represents and warrants that neither his execution of this Agreement nor the full and complete performance of his obligations hereunder will violate or conflict in any respect with any written or oral agreement or understanding with any person or entity.

 

13.6        Successors and Assigns This Agreement shall inure to the benefit of and shall be binding upon the Company (and its successors and assigns) and Executive and his heirs, executors and personal representatives.

 

13.7        Withholding Notwithstanding any other provision of this Agreement, the Company may withhold from amounts payable under this Agreement all federal, state, local and foreign taxes that are required to be withheld by applicable laws or regulations.

 

13.8        Severability The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.  If any provision of this Agreement shall be held invalid or unenforceable in part, the remaining portion of such provision, together with all other provisions of this

 



 

Agreement, shall remain valid and enforceable and continue in full force and effect to the fullest extent consistent with law.

 

13.9         No Assignment The rights and benefits of the Executive under this Agreement may not be anticipated, assigned, alienated or subject to attachment, garnishment, levy, execution or other legal or equitable process except as required by law.  Any attempt by the Executive to anticipate, alienate, assign, sell, transfer, pledge, encumber or charge the same shall be void.  Payments hereunder shall not be considered assets of the Executive in the event of insolvency or bankruptcy.

 

13.10      Survival.   This Agreement shall survive the termination of Executive’s employment and the expiration of the Term to the extent necessary to give effect to its provisions.

 

13.11      Captions The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

 

13.12      Counterparts This Agreement may be executed by the parties hereto in separate counterparts; each of which when so executed and delivered shall be an original but all such counterparts together shall constitute one and the same instrument.

 

13.13      Legal Fees and Expenses . Promptly following the Effective Date, the Company shall reimburse the Executive for legal fees and expenses incurred by Executive in negotiation of this Agreement up to the maximum of $2,000.

 


 

IN WITNESS WHEREOF, Executive and the Company have executed this Agreement as of the date first written above.

 

 

 

RITE AID CORPORATION

 

 

 

 

 

 

 

 

 

 

/s/ Robert B. Sari

 

 

 

 

 

 

By:

Robert B. Sari

 

 

Its:

Executive Vice President, General Counsel

 

 

 

 

 

 

 

 

 

 

EXECUTIVE

 

 

 

 

 

/s/ Ken Martindale

 

 

Ken Martindale

 



 

APPENDIX A

 

A “Change in Control of the Company” shall be deemed to have occurred if, as the result of a single transaction or a series of transactions, the event set forth in any one of the following paragraphs shall have occurred:

 

(1) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company’s then outstanding voting securities; or

 

(2) Incumbent Directors cease at any time and for any reason to constitute a majority of the number of directors then serving on the Board.  “Incumbent Directors” shall mean directors who either (A) are directors of the Company as of the Effective Date or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors to the Board); or

 

(3) there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation, other than:  (i) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 60% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation; or (ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company’s then outstanding voting securities; or

 

(4) the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least 60% of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.

 

“Affiliate” shall have the meaning set forth in Rule 12b-2 under Section 12 of the Exchange Act.

 



 

“Beneficial Owner” shall have the meaning set forth in Rule 13d-3 under the Exchange Act, except that a Person shall not be deemed to be the Beneficial Owner of any securities which are properly filed on a Form 13G.

 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

 

“Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include:  (i) the Company or any of its subsidiaries; (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its subsidiaries; (iii) an underwriter temporarily holding securities pursuant to an offering of such securities; or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 



 

APPENDIX B

 

The following is a list of all written agreements with any of Executive’s prior employers, as well as any other agreements to which Executive is subject, which includes any obligation of confidentiality, assignment of intellectual property, nonsolicitation or noncompetition.  If none, type “None”.

 

Employment Agreement dated December 14, 2005 with Pathmark Stores, Inc.

 

Any duties as a member of the Board of Directors of Intesource, Inc.

 



 

 

 

MAILING ADDRESS

 

P.O. Box 3165

 

Harrisburg, PA 17105

 

 

 

GENERAL OFFICE

 

30 Hunter Lane

 

Camp Hill, PA 17011

 

 

 

(717) 761-2633

 

Appendix C to Employment Agreement

 

Date

 

Name

Address

City, St Zip

 

Re:                                Severance Agreement and General Release

 

Dear Name:

 

We are interested in resolving cooperatively your separation of employment with Rite Aid Corporation (the Company), which will take place on (date), your Separation Date.  Toward this end, we propose the following Severance Agreement, which includes a General Release.

 

Whereas, the Company has previously entered into an employment agreement with you, dated (Date) (the Employment Agreement), which contains among other things, certain provisions regarding severance compensation payable upon termination of your employment with the Company under certain circumstances. Other than what is expressly set forth herein, the terms and conditions of the Employment Agreement shall remain in full force and effect.

 

The terms and conditions set forth in Paragraph 1 below will apply regardless of whether you decide to sign this Severance Agreement and General Release.  However, you will not be eligible to receive the payments and benefits set forth in Paragraph 2 below unless you sign and do not revoke this Severance Agreement and General Release, within the time period specified below.  (Please see Paragraph 20 below for what it means to revoke this Severance Agreement and General Release.)

 

You may consider for forty-five (45) days whether you wish to sign this Severance Agreement and General Release.  Since this Severance Agreement and General Release (“Agreement”) is a legal document, you are encouraged to review it with your attorney.

 

1.                                        General Terms of Termination . As noted above, whether or not you sign this Agreement:

 

(a)                                   Your last day of employment is (date) which is your Separation Date.  You will be paid for all time worked up to and including your termination.

 

(b)                                  You will be paid for earned but unused vacation days and any properly documented reasonable expenses incurred in connection with your employment through your Separation Date.

 

1



 

(c)                                   Except as contemplated by the Employment Agreement, your eligibility to participate in all other group benefits except Company sponsored health insurance including medical, dental, vision and prescription as an employee of the Company will end on your Separation Date.

 

(d)                                  You are required to comply with Paragraphs 6 and 7 below.

 

2.                                        Separation Payment .  Except with respect to the Accrued Benefits as defined in the Employment Agreement, if you sign this Agreement, agreeing to be bound by the General Release in Paragraph 3 below and the other terms and conditions of this Agreement described below, and comply with the requirements of this Paragraph 2 (other than the Accrued Benefits), you will receive the compensation and benefits as contemplated by the Employment Agreement. You will not be eligible for the payment and benefits described in Paragraph 2 unless:  (i) You sign this Agreement no later than forty five (45) days after you receive it, promptly return the Agreement to the Company after you sign it, and do not timely revoke it in accordance with paragraph 20 below; (ii) you have returned all Company property and documents in accordance with Paragraph 7 below.

 

3.                                        General Release .

 

(a)                                   In exchange for the consideration described in Paragraph 2 and except as contemplated under Paragraph 4 below, you release and forever discharge, to the maximum extent permitted by law, the Company and each of the other “Releasees” as defined below, from any and all claims, causes of action, complaints, lawsuits or liabilities of any kind with respect to the Company (collectively “Claims”) as described below which you, your heirs, agents, administrators or executors have or may have against the Company, or any of the other Releasees.

 

(b)                                  By agreeing to this General Release, you are waiving, to the maximum extent permitted by law and other than as contemplated by Paragraph 4 below, any and all Claims which you have or may have against the Company, or any of the other Releasees arising out of or relating to any conduct, matter, event or omission with respect to the Company existing or occurring before the Separation Date, including but not limited to the following:

 

(i)                                      any Claims having anything to do with your Employment Agreement or your employment with the Company or any of the Releasees;

 

(ii)                                   any Claims having anything to do with the termination of your employment with the Company or any of the Releasees;

 

(iii)                                any Claims for unpaid or withheld wages, severance or retention payments, benefits, bonuses, commissions and/or other compensation of any kind;

 

(iv)                               any Claims for reimbursement of expenses of any kind;

 

(v)                                  any Claims for attorneys’ fees or costs;

 

(vi)                               any Claims for any breach under the Employee Retirement Income Security Act (“ERISA”);

 

(vii)                            any Claims of discrimination and/or harassment based on age, sex, race, religion, color, creed, disability, handicap, citizenship, national origin, ancestry, sexual orientation, or any other factor protected by Federal, State or Local law as enacted or amended (such as the Age Discrimination in Employment Act, 29 U.S.C. §621 et.   seq.; Title VII of the Civil

 

2



 

Rights Act of 1964; the Americans with Disabilities Act, the Equal Pay Act; Civil Rights of People with Disabilities Act and Domestic Abuse Bias in Employment Law) and any Claims for retaliation under any of the foregoing laws;

 

(viii)                         any Claims regarding leaves of absence including, but not limited to, any Claims under the Family and Medical Leave Act;

 

(ix)                                 any Claims under the National Labor Relations Act;

 

(x)                                    any Claims under the Sarbanes-Oxley Act;

 

(xi)                                 any Claims under the Worker Adjustment and Retraining Notification Act (“WARN”);

 

(xii)                              any Claims for violation of public policy;

 

(xiii)                           any whistleblower or retaliation Claims;

 

(xiv)                          any Claims for emotional distress or pain and suffering; and/or

 

(xv)                             any other statutory, regulatory, common law or other Claims of any kind, including, but not limited to, Claims for breach of contract (other than as contemplated hereby), libel, slander, fraud, wrongful discharge, promissory estoppel, equitable estoppel and misrepresentation.

 

(c)                                   The term “Releasees” means: all and singularly, Rite Aid Corporation, Rite Aid HDQTRS. Corp., as well as any of their direct or indirect parent, subsidiary, related or affiliated companies, and each of their past and present employees, officers, directors, attorneys, owners, partners, insurers, benefit plan fiduciaries and agents, and all of their respective predecessors, successors and assigns.

 

(d)                                  It is important that you understand that this General Release includes all Claims known or unknown by you, those that you may have already asserted or raised as well as those that you have never asserted or raised.

 

4.                                        Non-Released Claims .  Notwithstanding anything in this Agreement to the contrary, the General Release in Paragraph 3 above does not apply to:

 

(a)                                   Any Claims for vested benefits under any retirement, 401(k), profit-sharing, deferred compensation or stock option plan or other plan or arrangement;

 

(b)                                  Any Claims to enforce the commitments set forth in this Agreement or the applicable provisions of the Employment Agreement that survive termination of your employment;

 

(c)                                   Any Claims to interpret or to determine the scope, meaning or effect of this Agreement or the applicable provisions of the Employment Agreement that survive termination of your employment;

 

(d)                                  Any Claims arising out of any conduct, matter, event or omission existing or occurring after the Separation Date;

 

(e)                                   Any Claim that can not be waived as a matter of law; or

 

3



 

(f)                                     Any Claim arising under or otherwise having anything to do with Sections 5.3 or 5.6 of the Employment Agreement to survive termination of your employment thereunder.

 

Further, the General Release does not prevent you from contacting or filing a charge with any federal, state or local government agency or commission.  However, the General Release does prevent you, to the maximum extent permitted by law, from obtaining any monetary or other personal relief for any of the Claims you have released in Paragraph 3.

 

5.                                        Adequacy of Consideration .  You acknowledge and agree that the consideration under Paragraph 2 above:

 

(a)                                   Constitutes adequate consideration to support your General Release in Paragraph 3 above; and

 

(b)                                  Fully compensates you for the Claims you are releasing.

 

For purposes of this Agreement, “consideration” means something of value to which you are not already entitled.

 

6.                                        Prohibition on Your Using or Disclosing Certain Information . Regardless of whether you sign this Agreement, to the extent provided in Section 6 of the Employment Agreement, you are prohibited from using or disclosing confidential and/or proprietary information which you acquired in the course of your employment with the Company or its predecessors, and which is not generally known by or readily accessible to the public.

 

7.                                        Company Property and Documents .  Regardless of whether you sign this Agreement, and as a condition of receiving the payment set forth in Paragraph 2 above, to the extent provided in Section 6 of the Employment Agreement you must return to the Company, retaining no copies , all Company property, keys, documents (hard copy or electronic), forms, correspondence, computer programs, memos, disks, DVDs and any other Company property in your possession or control.

 

8.                                        Confidentiality of this Agreement .  You and the Company and its affiliates each agree that, at all times, the existence, terms and conditions of this Agreement will be kept secret and confidential and will not be disclosed voluntarily to any third party, except:  (i) to your spouse, if applicable, (ii) to the extent required by law; (iii) in connection with any Claim to enforce, interpret or determine the scope, meaning, or effect of the Agreement; or (iv) to obtain confidential legal, tax or financial advice with respect thereto.

 

9.                                        Cooperation .  To the extent provided in Section 5.3 of the Employment Agreement, you agree that, upon reasonable request, you will meet with representatives of the Company, Rite Aid HDQTRS. Corp., or their respective parent or subsidiary company representatives and provide any information you acquired during the course of your employment relating in any way to any disputes or other matters involving the Company or any Releasee (as defined above). You further agree that you will cooperate fully with the Company relating to any matter in which you were involved or which you have knowledge by virtue of your employment with the Company, including any existing or future litigation involving the Company, whether administrative, civil or criminal in nature in which and to the extent the Company deems your cooperation necessary.

 

10.                                  Non-Disparagement .  You and the Company agree that neither party will make any negative comments or disparaging remarks, in writing, orally or electronically, about the other party or any other Releasee (as defined above) and their respective products and services.  However, nothing in

 

4



 

this Agreement is intended to or shall be interpreted to restrict either party’s right and/or obligation:  (i) to testify truthfully in any forum; or (ii) to contact, cooperate with or provide information to any government agency or commission.

 

11.                                  Resignation of Positions . In connection with the termination of your employment by the Company, you hereby resign from all positions you may hold as an officer or director of the Company and it subsidiaries and affiliates, and the Company hereby accepts such resignations. You agree to execute all such instruments and take all such other actions as the Company may reasonably deem necessary or desirable to evidence or accomplish the foregoing in full.

 

12.                                  Governing Law and Forum .  This Agreement shall be governed by and construed in accordance with the laws of Pennsylvania, where this Agreement is entered into, without giving effect to any conflict of law provisions.  Any court action instituted by you or on your behalf relating to in any way to this Agreement, or your employment or termination of employment with the Company or any Releasee, shall be filed exclusively in the Cumberland County Court of Common Pleas in the Commonwealth of Pennsylvania or in the United States District Court for the Middle District of Pennsylvania, and you consent to the jurisdiction and venue of these courts.

 

13.                                  Statement of Non-Admission .  Nothing in this Agreement is intended as or shall be construed as an admission or concession of liability or wrongdoing by you, the Company or any Releasee as defined above.  Rather, the proposed Agreement is being offered for the sole purpose of settling cooperatively and amicably any and all possible disputes described in Paragraph 3.

 

14.                                  Interpretation of Agreement .  Nothing in this Agreement is intended to violate any law or shall be interpreted to violate any law.  If any paragraph or part or subpart of any paragraph in this Agreement or the application thereof is construed to be overbroad and/or unenforceable, then the court making such determination shall have the authority to narrow the paragraph or part or subpart of the paragraph as necessary to make it enforceable and the paragraph or part or subpart of the paragraph shall then be enforceable in its/their narrowed form.  Moreover, each paragraph or part or subpart of each paragraph in this Agreement is independent of and severable (separate) from each other.  In the event that any paragraph or part or subpart of any paragraph in this Agreement is determined to be legally invalid or unenforceable by a court and is not modified by a court to be enforceable, the affected paragraph or part or subpart of such paragraph shall be stricken from the Agreement, and the remaining paragraphs or parts or subparts of such paragraphs of this Agreement shall remain in full, force and effect.

 

15.                                  Entire Agreement .  This Agreement and the applicable provisions of the Employment Agreement constitutes the entire agreement between the parties and supersedes any and all prior representations, agreements, written or oral, expressed or implied, by the Company or any Releasee arising out of or relating in any way to your employment or the termination of your employment with any Releasee. This Agreement may not be modified or amended other than by an agreement in writing signed by you and either the Vice President & Assistant General Counsel or the Senior Director of Corporate Human Resources of Rite Aid HDQTRS. Corp.

 

16.                                  Acknowledgment .  You acknowledge and agree that, subsequent to the termination of your employment, you shall not be eligible for any payments from the Company or any of the Releasees or any benefits arising out of your employment with any of the Releasees, except as expressly set forth in this Agreement or the Employment Agreement.

 

17.                                  Headings .  The headings contained in this Agreement are for convenience of reference only and are not intended, and shall not be construed, to modify, define, limit, or expand the intent of the

 

5



 

parties as expressed in this Agreement, and they shall not affect the meaning or interpretation of this Agreement.

 

18.                                  Days .  All references to a number of days throughout this Agreement refer to calendar days.

 

19.                                  Representations .  You agree and represent that:

 

(a)                                   You have read carefully the terms of this Agreement, including the General Release;

 

(b)                                  You have had an opportunity to and have been encouraged to review this Agreement, including the General Release, with an attorney;

 

(c)                                   You understand the meaning and effect of the terms of this Agreement, including the General Release;

 

(d)                                  You were given forty-five (45) days to determine whether you wished to sign this Agreement, including the General Release;

 

(e)                                   Your decision to sign this Agreement, including the General Release, is of your own free and voluntary act without compulsion of any kind;

 

(f)                                     No promise or inducement not expressed in this Agreement or the Employment Agreement has been made to you; and

 

(g)                                  You have adequate information to make a knowing and voluntary waiver.

 

20.                                  Revocation Period .  If you sign this Agreement, you will retain the right to revoke it for seven (7) days.  If you revoke this Agreement, you are indicating that you have changed your mind and do not want to be legally bound by this Agreement.  The Agreement shall not be effective until after the Revocation Period has expired without your having revoked it.  To revoke this Agreement, you must send a certified letter to the following address:  Steven Chesney, Senior Director of Corporate Human Resources, Rite Aid HDQTRS. Corp., 30 Hunter Lane, Camp Hill, PA 17011.  The letter must be post-marked within seven (7) days of your execution of this Agreement.  If the seventh day is a Sunday or federal holiday, then the letter must be post-marked on the following business day.  If you revoke this Agreement on a timely basis, you shall not be eligible for the consideration set forth in Paragraph 2.

 

21.                                  Offer Expiration Date .  As noted above, you have forty-five (45) days to decide whether you wish to sign this Agreement.  If you do not sign this Agreement within 45 days of the date you receive it, then this offer is withdrawn and you will not be eligible for the consideration set forth in Paragraph 2 above.

 

If you agree with the all of the terms of this Agreement, please sign below, indicating that you understand, agree with and intend to be legally bound by this Agreement, including the General Release, and return the signed Agreement to Steven Chesney at the above address.

 

6



 

We wish you the best in the future.

 

 

 

Sincerely,

 

 

 

 

 

 

 

 

 

UNDERSTOOD AND AGREED,

 

 

INTENDING TO BE LEGALLY BOUND:

 

 

 

 

 

 

 

 

Name

 

 

 

 

 

 

 

 

Date

 

 

 

 

 

 

 

 

Witness

 

 

 

7



 

APPENDIX D

 

LISTING OF PERMITTED ACTIVITIES

 

Serving on the Board of Directors of Intesource, Inc.

 




QuickLinks -- Click here to rapidly navigate through this document


Exhibit 31.1

Certification of CEO

I, Mary F. Sammons, Chief Executive Officer, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the "Registrant");

2.
Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.
The Registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5.
The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: January 7, 2009


 

 

By:

 

/s/ MARY F. SAMMONS

Mary F. Sammons
Chairman and Chief Executive Officer



QuickLinks

Certification of CEO

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 31.2


Certification of CFO

I, Frank G. Vitrano, Chief Financial Officer and Chief Administrative officer, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the "Registrant);

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.
The Registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

d.
Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the can of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5.
The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the registrant's board of directors:

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: January 7, 2009


 

By:

 

/s/ FRANK G. VITRANO

Frank G. Vitrano
Chief Financial Officer and
Chief Administrative Officer



QuickLinks

Certification of CFO

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 32


Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

        In connection with the Quarterly Report on Form 10-Q of Rite Aid Corporation (the "Company") for the quarterly period ended November 29, 2008 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mary F. Sammons, as Chief Executive Officer of the Company, and Frank G. Vitrano as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of her/his knowledge:


/s/ MARY F. SAMMONS


 

 
Name:   Mary F. Sammons    
Title:   Chief Executive Officer    
Date:   January 7, 2009    

/s/ FRANK G. VITRANO


 

 
Name:   Frank G. Vitrano    
Title:   Chief Financial Officer    
Date:   January 7, 2009    



QuickLinks

Certification of CEO and CFO Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002